Protocol CY 4033 CONFIDENTIAL 
PROTOCOL CY 4033 
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral 
Sclerosis (ALS) Who Completed VITALITY -ALS (CY 4031) 
Product Number: CK-[ADDRESS_541081] Name: [CONTACT_428060]: 2016-002629-13 
Sponsor: Cytokinetics, Inc. 
[ADDRESS_541082] Grand A venue 
South San Francisco, [LOCATION_004] [ZIP_CODE] 
Original Protocol: 13 July 2016 
Lead Investigator Signature: ~-~- L 
Version: 13 July 2016 CONFIDENTIAL 
Do Not Copy or Reproduce 
Without Consent of Cytokinetics, Inc. 
Page 1 
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541083] 
South San Francisco, [LOCATION_004]  [ZIP_CODE] ([PHONE_8890] (Main Telephone) ([PHONE_7282] (Main Facsimile)  
Sponsor’s Study Contact [CONTACT_352509], Clinical Operations  
Cytokinetics, Inc.  
[EMAIL_6754]  
([PHONE_8891] (Office Telephone) ([PHONE_8892] (Mobile Telephone)  
 Sponsor’s Medical Monitor Stacy Rudnicki, MD Director, Clinical Research & Development  
Cytokinetics, Inc.  
[EMAIL_8144] ([PHONE_7285] (Mobile Telephone)  
([PHONE_7284] (Office Telephone) (650) 624- 3225 (Office Facsimile)  
 
Lead Investigator  Jeremy Shefner, MD, PhD  
Professor & Chair of Neurol ogy 
Barrow Neurological Institute  
[EMAIL_6755] ([PHONE_7286] (Mobile Telephone)  
Study Site  Multi-National 
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 3 INVESTIGATOR PROTOCO L AGREEMENT PAGE 
 
I agree: 
• To assume responsibility for the proper conduct of the study at this site. 
• To conduct the study in compliance with this protocol, any future amendments, and 
with any other study conduct procedures provided by [CONTACT_352510]. 
• Not to amend the protocol without agreement, prior review, and written approval 
from the Institutional Review B oard (IRB) , Research Ethics Board (REB), or Ethics 
Committee  (EC), except where necessary to eliminate an immediate hazard to the 
patients. 
• That I am thoroughly familiar with the appropriate use of the investigational product 
(tirasemtiv ), as described in this protocol and any other information provided by [CONTACT_352511], but not limited to, the following: the current Investigator’s 
Brochure (IB) or equivalent document. 
• That I am aware of, and will comply with, “Good Clinical Practices” (GCP) and all  
applicable regulatory requirements.  
• To ensure that all persons assisting me with the study are adequately informed about 
the Cytokinetics investigational product ( tirasemtiv ) and of their study- related duties 
and functions as described in the protocol. 
• That I have been informed that certain regulatory authorities require the Sponsor to 
obtain and supply, as necessary, details about the Investigator’s ownership interest in 
the Sponsor or the investigational product ( tirasemtiv ), and more generally about 
his/her financial ties with the Sponsor.  Cytokinetics will use and disclose the 
information solely for the purpose of complying with regulatory requirements. 
Hence I: 
Agree to supply Cytokinetics with any necessary information regarding ownership interest and financial ties (including those of my spouse and dependent children); 
Agree to promptly update this information if any relevant changes occur during the course of 
the study and for 1 year following completion of the study; and 
Agree that Cytokinetics may  disclose any information it has about such ownership interests 
and financial ties to regulatory authorities.  
  
Investigator Name:  ______________________________________________________ 
 
Investigator Signature: ________________________________  Date: ________________ 
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541084] OF ABBREVIATION S AND DEFINITIONS OF  TERMS ..................................................9  
1. INTRODUCTION  ......................................................................................................11  
1.1. Background on Tirasemtiv  ..........................................................................................11  
1.2. Rationale for Tirasemtiv  in the Potential Treatment of Amyotrophic Lateral 
Sclerosis ......................................................................................................................11  
1.3. Overview of Tirasemtiv  Nonclinical Studies  ..............................................................12  
1.4. Overview of Tirasemtiv  Clinical Studies  ....................................................................13  
1.4.1.  Phase 1 and Phase 2a Studies  .....................................................................................13  
1.4.2.  Phase 2b Clinical Trial in Patients with ALS (CY 4026; BENEFIT -ALS) ...............13  
1.4.3.  Phase 3 Clinical Trial in Patients with ALS (CY 4031; VITALITY -ALS) ...............17  
2. STUDY OBJECTIVES  ..............................................................................................29  
2.1. Primary Objective  .......................................................................................................29  
2.1.1.  Primary Endpoint ........................................................................................................29  
2.2. Secondary Objectives  .................................................................................................29  
2.2.1.  Secondary Endpoints ..................................................................................................29  
3. STUDY OVERVIEW  .................................................................................................31  
3.1. Tirasemtiv  Dose Rationale in the Open Label Extension Study .................................32  
3.2. Riluzole Dose Adjustment Rationale  ..........................................................................32  
4. STUDY POPULATION  .............................................................................................33  
4.1. Inclusion Criteria  ........................................................................................................33  
4.2. Exclusion Criteria  .......................................................................................................33  
5. STUDY PROCEDURES  ............................................................................................35  
5.1. Day 1 Clinic Visit .......................................................................................................35  
5.2. Week 2 Phone Call .....................................................................................................36  
5.3. Week 4 Clinic Visit  ....................................................................................................36  
5.4. Week 6 Phone Call .....................................................................................................36  
5.5. Week 8 Clinic Visit  ....................................................................................................36  
5.6. Week 10 Phone Call ...................................................................................................37  
5.7. Week 12 Clinic Visit  ..................................................................................................37  
5.8. Week 24 Clinic Visit  ..................................................................................................38  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 5 5.9. Week 36 Clinic Visit  ..................................................................................................38  
5.10.  Week 48 Clinic Visit  ..................................................................................................39  
5.11.  Ongoing Clinic Visits Every 12 Weeks ......................................................................39  
5.12.  Tirasemtiv  Discontinuation Visit ................................................................................40  
5.13.  28 Day Safety Follow- Up Visit ..................................................................................41  
5.14.  Visit Windows  ............................................................................................................41  
5.15.  Timing of Doses .........................................................................................................42  
5.16.  Concomitant Medications ...........................................................................................42  
5.17.  PK Sample Collection  .................................................................................................43  
5.18.  Clinical Safety Assessments  .......................................................................................43  
5.18.1.  Clinical La boratory Evaluations .................................................................................43  
5.18.2.  Vital Signs  ..................................................................................................................43  
5.18.3.  Suicidality Assessment  ...............................................................................................44  
5.19.  Clinical and Pharmacodynamic Outcome Measures  ..................................................44  
5.19.1.  ALS Functional Rating Scale -Revised (ALSFRS -R) .................................................44  
5.19.2.  Slow Vital Capacity (SVC)  ........................................................................................[ADDRESS_541085] .......................................................................46  
6.2. Dose Administration of Tirasemtiv  ............................................................................46  
6.3. Dose Adjustment Criteria  ...........................................................................................46  
6.4. Treatment Interrup tion ................................................................................................47  
6.5. Daily Dosing Diary  .....................................................................................................47  
6.6. Tirasemtiv  Handling and Disposal ..............................................................................47  
6.7. Tirasemtiv  Accountability  ..........................................................................................47  
7. ADVERSE EVENTS AND S AFETY ASSESSMENTS  ...........................................48  
7.1. Definitions  ..................................................................................................................48  
7.1.1.  Adverse Event  .............................................................................................................48  
7.1.2.  Serious Adverse Events ..............................................................................................49  
7.2. Adverse Event Severity  ..............................................................................................50  
7.3. Assessment of Causality to Tirasemtiv  .......................................................................51  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 6 7.4. Procedures for Eliciting and Recording Adverse Events ...........................................51  
7.4.1.  Eliciting Adverse Events  ............................................................................................51  
7.4.2.  Recording of Adverse Events  .....................................................................................51  
7.4.3.  Adverse Event Term  ...................................................................................................51  
7.4.4.  Recording Serious Adverse Events  ............................................................................52  
7.4.5.  Pregnancy  ...................................................................................................................52  
7.5. Reporting Period for Adverse Events .........................................................................52  
7.5.1.  Follow-Up of Adverse Events ....................................................................................53  
7.6. Serious Adverse Events Require Immediate Reporting  .............................................53  
8. STATISTICAL METHODS  .......................................................................................54  
8.1. General Considerations ...............................................................................................54  
8.1.1.  General Approach  .......................................................................................................54  
8.1.2.  Sample Size  ................................................................................................................54  
8.2. Analysis Sets  ...............................................................................................................54  
8.2.1.  Safety Analysis Set (SAS)  ..........................................................................................54  
8.2.2.  Efficacy Analy sis Set (EAS)  ......................................................................................55  
8.2.3.  Pharmacokinetic Set (PKS)  ........................................................................................55  
8.3. Study Endpoints  ..........................................................................................................55  
8.3.1.  Primary Endpoint ........................................................................................................55  
8.3.2.  Secondary Endpoints ..................................................................................................55  
[IP_ADDRESS].  Time-to-Event Endpoints ............................................................................................55  
[IP_ADDRESS].  Change from Baseline Endpoints  ...............................................................................55  
[IP_ADDRESS].  Slope Endpoints ..........................................................................................................55  
8.4. Statistical Analyses  .....................................................................................................56  
8.4.1.  Patient Disposition  ......................................................................................................56  
8.4.2.  Demographics and Other Baseline Characteristics  .....................................................56  
8.4.3.  Efficacy Analyses  .......................................................................................................56  
[IP_ADDRESS].  Change from Baseline Endpoints  ...............................................................................56  
[IP_ADDRESS].  Time-to-Event Endpoints ............................................................................................56  
8.4.4.  Hypothesis Testing and Multiplicity  ..........................................................................57  
8.4.5.  Sensitivity Analysis  ....................................................................................................57  
8.4.6.  Subgroup Efficacy Analyses .......................................................................................57  
8.5. Safety Analysis  ...........................................................................................................57  
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541086] / Ethics Committee / Research Ethics Board  ..................60  
9.6. Informed Consent .......................................................................................................61  
9.7. Records .......................................................................................................................61  
9.8. Reference to Good Clinical Practices (GCP)  ..............................................................61  
10. REFERENCES  ...........................................................................................................62  
APPENDIX A.  SCHEDULE OF EVENTS  ................................................................................63  
APPENDIX B.  SUBSTRATES OF CYP2B6 , 2C8, 2C9, AND 2C19 .......................................64  
APPENDIX C.  SUBSTRATES, INHIBITO RS AND INDUCERS OF CYP1A2  .....................65  
 
 
  
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541087] OF TABLES  
Table 1:  Exposure to Tirasemtiv  at the NOAEL in Rat and Dog .............................................12  
Table 2:  Estimated IC 50, kinact, and K I Values for Tirasemtiv  Time-Dependent 
Inhibition .....................................................................................................................13  
Table 3:  Percent Predicted Slow Vital Capacity in BENEFIT -ALS ........................................15  
Table 4:  Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  ...........................18  
Table 5:  Completed Phase 2b Clinical Studies with Tirasemtiv  ...............................................26  
Table 6:  Ongoing Phase 3 Clinical Study with Tirasemtiv  .......................................................28  
Table 7:  Study Dosing Plan ......................................................................................................31  
Table 8:  Visit Windows  ............................................................................................................42  
Table 9:  Pharmacokinetic (PK) Samples  ..................................................................................43  
Table 10:  Tirasemtiv  Investigational Product .............................................................................[ADDRESS_541088] OF FIGURES  
Figure 1: Changes from Baseline in Percent Predicted Slow Vital Capacity in 
BENEFIT -ALS ...........................................................................................................14  
Figure 2: Change from Baseline to Average after  8 and 12 Weeks in Percent Predicted 
Slow Vital Capacity  ....................................................................................................16  
Figure 3: Study Visit Diagram  ...................................................................................................31  
 
 
 
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541089] OF ABBREVIATION S AND DEFINITIONS OF TERMS 
Abbreviation  Definition  
AE adverse event  
ALS amyotrophic lateral sclerosis  
ALT alanine aminotransferase (alanine transaminase)  
ALSFRS-R ALS Functional Rating Scale -Revised 
AST aspartate aminotransferase (aspartate transaminase)  
AUCinf  area under the concentration -time curve (extrapolated to infinity)  
AUC area under the plasma concentration -time curve (during dosing interval) 
BID twice a day  
BMI body mass index 
CBC Complete blood count (hematology clinical laboratory evaluations)  
CFR Code of Federal Regulations  
CI confidence interval  
CNS central nervous system  
CPK  creatine phosphokinase  
Cmax  maximum observe d plasma concentration  
CTCAE Common Terminology Criteria for Adverse Events  
CYP cytochrome P450 
DMC Data Monitoring Committee  
DPS diaphragm pacing system  
EC Ethics Committee  
ECG Electrocardiogram  
eCRF electronic case report form  
EudraCT European Union Drug Regulating Authorities Clinical Trials  
FDA Food and Drug Administration 
GCP Good Clinical Practices  
GLP Good Laboratory Practices  
hERG human ether -à-go-go related gene  
IB Investigator’s Brochure  
IC50 half maximal inhibitory concentration  
ICF informed consent form 
ICH  International C ouncil on Harmonisation  
INR international normalized ratio  
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541090] level  
PD Pharmacodynamics  
PI [INVESTIGATOR_244278](s)  
PKS pharmacokinetic set  
QD once daily  
REB Research Ethics Board  
SAE serious adverse event  
SAS safety analysis set  
SD standard deviation  
SE standard error  
SNIP Sniff Nasal Inspi[INVESTIGATOR_427999] -emergent adverse event  
TnC troponin C  
TSH thyroid stimulating hormone  
UA Urinalysis 
WHO World Health Organization  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 11 1. INTRODUCTION 
1.1. Background on Tirasemtiv  
Tirasemtiv  (formerly CK -2017357) is a novel small molecule activator of fast skeletal muscle 
troponin, intended to improve skeletal muscle function in disease states associated with m uscular 
weakness or fatigue, including amyotrophic lateral sclerosis ( ALS), without affecting the 
structure of muscle itself.  Tirasemtiv  selectively binds to the fast skeletal muscle troponin 
complex and slows the rate of calcium release from troponin C ( TnC).  This increases the affinity 
of TnC for calcium and thus sensitizes the sarcomere to calcium.  Tirasemtiv  is selective for fast 
skeletal muscle troponin with little effect on slow skeletal muscle troponin and no effect on 
cardiac muscle troponin. By [CONTACT_428028], tirasemtiv  shifts the calcium -force relationship of muscle fiber s leftward, amplifying the 
response of muscle to submaximal nerve stimulation and thereby [CONTACT_428029].  Tirasemtiv  decreases  muscle fatigability in several preclinical models of exercise performance, 
presumably by [CONTACT_428030] 
(Russell, Hartman et al. 2012).  In a transgenic mouse model of ALS with functional deficits, 
single doses of tirasemtiv  significantly increased submaximal isometric force, forelimb grip 
strength, grid hang time, and running performance on a rotating rod.  Additionally, diaphragm force and tidal volume were significantly higher ( Hwee, Kennedy et al. 2014 ).  Acute and 
reversible clinical signs of intolerance were the dose- limiting toxicities in preclinical testing.  
The pharmacological profile of tirasemtiv  is unique in that it is a direct and selective functional 
activator of fast skeletal muscle; as such, it could benefit patients with a wide variety of disorders 
characterized by [CONTACT_428031].  
In a Phase 2b study that enrolled 711 patients with ALS, CY 4026, also known as BEN EFIT-
ALS, 12 weeks’ treatment with tirasemtiv  was associated with statistically significant and 
potentially clinically meaningful reductions in the decline in slow vital capacity (SVC) versus placebo (see Section 1.4.2).   This observation led to CY 4031, also known as VITALITY- ALS, 
a Phase 3 double-blind placebo -controlled study of tirasemtiv  administered for 52 weeks with a 
projected enrollment of 600 patients.  The current study, CY 4033, is the open label extension for 
those patients who complete participation on study drug in the CY 4031 ( VITALITY -ALS) 
study.   
1.2. Rationale for Tirasemtiv  in the Potential Treatment of Amyotrophic 
Lateral Sclerosis 
Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells in the brain and spi[INVESTIGATOR_352478].  In ALS, progressive death of motor neurons leads to denervation of skeletal muscles.  Surviving motor units attempt to compensate for dying ones by 
[CONTACT_352515] ( a process called sprouting) but are only partially successful 
(Kiernan, Vucic et al. 2011).  Over time, progressive denervation and its consequent skeletal 
muscle atrophy lead to weakness, fatigue, and eventually complete paralysis and death, primarily 
from respi[INVESTIGATOR_11800].   
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541091].  Rilutek® (riluzole, [COMPANY_011]-Aventis U.S. LLC) is the only 
medication approved for the treatment of ALS, and has a modest benefit on survival ( Lacomblez, 
Bensimon et al. 1996).  Two interventions that contribute greatly to the overall welfa re and 
survival of ALS patients are the use of enteral feeding and ventilatory support. 
To date, there are no available treatments that can improve skeletal muscle function , and in 
particular  respi[INVESTIGATOR_4806].  B ecause tirasemtiv  has been demonstrated both to amplify 
skeletal muscle force production in response to diminished neuronal input and to delay the onset 
and reduce the magnitude of skeletal muscle fatigue during repeated or sustained efforts, it may 
be useful in the treatment of patients with AL S.  
1.3. Overview of Tirasemtiv  Nonclinical Studies  
A brief summary of the nonclinical safety and pharmacokinetics (PK) of tirasemtiv  is provided in 
this section.  Additional information concerning nonclinical assessments of the pharmacology, PK, and safety of tirasemtiv  is available in the Investigator’s Brochure (IB).  
Tirasemtiv  was evaluated in a series of Good Laboratory Practices (GLP) nonclinical safety 
pharmacology and toxicology studies, including single- and repeat -dose toxicity studies 
performed in Spr ague-Dawley rats up to 26 weeks and beagle dogs up to 39 weeks, teratology 
studies in rats and rabbits, single-dose phototoxicity studies in rats, and a core battery of 
genotoxicity tests.  
In rats, following administration of tirasemtiv  for 26 weeks at do se levels of 0, 5, 15 and 
30 mg/kg/day , target organ effects were observed at levels of 15 and 30 mg/kg/day and consisted 
of fibrosis and/or atrophy of the mandibular salivary glands and hepatocellular hypertrophy of 
the liver.  The finding in the liver was fully recovered and the findings in the salivary glands were partially recovered at 30  mg/kg/day following the recovery period.  The no observed 
adverse effect level (NOAEL) in  rats was considered to be 15 mg/kg/day in this study.  The 
exposures at the end of the study attained at the NOAEL are shown in Table 1 below. 
In dogs, administration of tirasemtiv  for 39 weeks at dose levels of 0, 6, 20 and 50 mg/kg/day  
resulted in adverse but reversible clinical signs at 5 0 mg/kg/day, non- adverse effects on body 
weight at all dose levels, and a decrease in food consumption at the high dose.  Tirasemtiv  
caused partially reversible increases in  aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) at 50 mg/kg/day, with  a reversible increase in  total bilirubin in females 
at 50 mg/kg/day and a reversible increase in creatine kinase and aldolase activities in individual males and females at 50 mg/kg/day.  The NOAEL in dogs was considered to be 20 mg/kg/day in 
this study.
  The exposures at the end of the study attained at the NOAEL are shown in Table 1 
below. 
Table 1: Exposure to  Tirasemtiv  at the NOAEL in Rat and Dog  
 26-Week Rat Toxicity  Study 39-Week Dog Toxicity Study 
M F M F 
Dose (mg/kg/day) 15 15 20 20 
Cmax (μg/mL)  25.1 46.5 27.0 20.9 
AUC (μg•h/mL) 228.5 589.0 128.8 80.6 
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541092] of tirasemtiv  on the human ether -à-go-go related gene (hERG) channel 
(inhibition of 19.5% at 250 µM ).  Findings in cardiovascular, central nervous system (CNS), and 
respi[INVESTIGATOR_428000]/or limited duration.  
The potential of tirasemtiv  to inhibit cytochrome P450 (CYP) enzymes (CYP1A2, 2A6, 3A4, 
2B6, 2C8, 2C9, 2C19, 2D6, and 2E1) was studied in vitro  in human liver microsomes at 
concentrations up to [ADDRESS_541093] and time -dependent inhibitions were assessed . 
Tirasemtiv  did not inhibit CYP3A4, 2D6, 2A6, or 2E1 with each half maximal inhibitory 
concentration ( IC50) exceeding the highest concentrations tested .  Tirasemtiv  was found to be a 
direct and time-dependent inhibitor of multiple CYP450 isoforms ( CYP1A2,  2B6, 2C8, 2C9, and 
2C19).  Kinetic parameters for the time -dependent inhibition, including the time -dependent IC50 
(inhibitory constant following 20 or 30 minute pre-incubation with microsomes + NADPH), 
maximum rate constant for inactivation (k inact) and inactivation constant (K I), are shown in 
Table 2. 
Table 2: Estimated  IC50, kinact, and K I Values for Tirasemtiv  Time-Dependent 
Inhibition  
CYP Isoform  Time-Dependent IC50 (µM) kinact (min-1) KI (µM) 
CYP1A2 5.5 0.031 1.9 
CYP2B6 21 0.035 26 
CYP2C8 80 0.057 46 
CYP2C9 69 0.021 34 
CYP2C19  4 0.051 11 
1.4. Overview of Tirasemtiv  Clinical Studies  
1.4.1. Phase 1 and Phase 2a Studies  
Tirasemtiv  has been evaluated in three completed Phase 1  clinical trials in healthy volunteers 
(CY 4011, CY 4012 and CY 4013), t hree Phase 2 a clinical trials (CY 4021, CY 4024, and 
CY 4025) in patients with ALS ; a Phase 2 a clinical trial in patients with claudication secondary 
to peripheral artery disease (CY 4022) a nd a Phase 2 a clinical trial in patients with myasthenia 
gravis (CY 4023) ha ve also been completed.  The Phase 1  and Phase 2a clinical studies are 
summarized in Table 4.  Additional details are available in the IB. 
1.4.2. Phase 2b Clinical Trial in Patients with ALS (CY 4026 ; BENEFIT- ALS) 
CY 4026, also known as BENEFIT- ALS (Blinded Evaluation of N euromuscular E ffects and 
Functional I mprovement with Tirasemtiv  in ALS), was a Phase 2 b clinical trial in which 
711 patients with  ALS were enrolled from 73 centers in North America and Western Europe into 
open-label treatment with tirasemtiv  125 mg twice a day .  Subsequently, patients who completed 
one week of open-label treatment were randomized 1:1 to double- blind treatment with either 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 14 tirasemtiv  (titrated at weekly intervals to each patient’s maximum tolerated dose ≤ 250 mg twice 
daily) or placebo for 12 weeks .  Clinical assessments were made at baseline (i.e., prior to 
treatment with open -label tirasemtiv ), after 4, 8, and [ADDRESS_541094] one dose of 
double-blind study drug. 
The primary endpoint in CY 4026, the mean change from baseline in the ALS Functional Rating 
Scale in its revised form (ALSFRS -R), was not statistically different between treatment groups. 
The least squares mean (LSM) changes from baseline were −2.40 in the placebo group and −2.98 
in the tirasemtiv  group. The LSM ± standard error (SE) difference between treatment groups 
(i.e., tirasemtiv  response minus placebo response) was −0.58 ± 0.366 (95% confidence interval 
(CI): −1.30, 0.14; p = 0.114).  Although CY 4026 did not achieve its primary efficacy endpoint, 
two pre-specified secondary endpoints, both reflective of skeletal muscle function, were positively impacted.   
Treatment with tirasemtiv  resulted in a statistically significant and potentially clinically  
meaningful reduction in the decline of vital capacity ( measured as SVC ) which assesses strength 
of the skeletal muscles responsible for breathing.  The percent predicted SVC declined -3.12 
percentage points (±0.90) from the baseline value over 12 weeks on tirasemtiv  compared to a 
decline of -8.66 percentage points (±0.80) in the placebo group (p= <0.0001).  This pre- specified 
secondary efficacy endpoint declined less on tirasemtiv  than on placebo at each assessment time 
point and this difference persisted through 28 days after discontinuation of double-blind 
treatment  (Figure 1, Table 3).  Vital capacity  has been shown to be an important predictor of 
disease progression and survival in prior clinical trials of patients with ALS.  
Figure 1: Changes from Baseline in Percent Predicted Slow Vital Capacity in 
BENEFIT- ALS 
 

Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 15 Table 3: Percent Predicted Slow Vital Capacity in BENEFIT -ALS 
Slow Vital Capacity  Placebo 
(n = 210) Tirasemtiv  
(n = 178) All 
(N = 388) 
Baseline 
(prior to the one week Open- Label phase)  
(% Predicted, mean ± Standard Deviatio n [SD]) 89.7 (17.2) 85.7 (19.3) 87.8 (18.3) 
Time Point during the Double -Blind 
Treatment  Changes from Baseline  
(LSM ± SE)  p-value 
Week 4 -3.89 (0.62) -0.99 (0.68) 0.001 
Week 8 -5.81 (0.68) -2.85 (0.77) 0.004 
Week 12 -8.66 (0.80) -3.12 (0.90) <0.0001 
 Slope of decline  
(Percentage Points per day)   
Baseline to Week 12  -0.0905 -0.0394 0.0006 
 Changes from Baseline  
(LSM ± SE)   
Week 13 ([ADDRESS_541095] DB dose)  -8.03 (0.77) -3.75 (0.84) 0.0002 
Week 16 ([ADDRESS_541096] DB dose)  -10.30 (0.90) -5.39 (0.98) 0.0002 
As shown in Figure 2, tirasemtiv  reduced the decline in SVC compared to placebo regardless of 
age, gender, riluzole use, or body mass index ( BMI).  Subgroups with the largest and most 
significant diff erences in SVC on tirasemtiv  versus placebo (change from baseline to mean SVC 
after 8 and 12 weeks of double-blind treatment) were: females (6.84%, p = 0.012); non- riluzole 
users (6.55%, p = 0.0005); and patients with baseline SVC ≥ median at baseline (6.0 2%, 
p < 0.0001).   
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 16 Figure 2: Change from Baseline to Average after [ADDRESS_541097] rength 
Mega-Score, a measure of strength based on the percent change from baseline from several 
muscle groups in each patient, declined more slowly on tirasemtiv  versus placebo (p = 0.016 for 
the difference in slope of decline); however, there were no diff erences at any time point that 
reached statistical significance.  The rate of decline for Sniff Nasal Inspi[INVESTIGATOR_13955] (SNIP) 
was not statistically significantly different between tirasemtiv  and placebo (p = 0. 21); however, 
SNIP decreased statistically significantly more on tirasemtiv  compared with placebo at 4 and 
12 weeks (p values at 4, 8, and 12 weeks were 0.012, 0.066, 0.050, respectively).  No differences in Maximum Voluntary Ventilation (MVV) and Hand Grip Fatigue were observed on tirasemtiv  
versus placebo.   
Serious adverse event s (SAEs) during double-blind treatment were more frequent on tirasemtiv  
than on placebo (9.0% vs. 5.4%).  The most common SAE was respi[INVESTIGATOR_1399], which 
occurred in one patient on tirasemtiv  and three patients on placebo, while confusional state and 
delirium occurred in two patients on tirasemtiv  and no patients on placebo.  Of patients receiving 
at least one dose of double-blind study drug, more patients on tirasemtiv  withdrew from the trial 
following randomization than on placebo (97 vs. 26 patients, respectively).  A dverse event s 
(AEs) more common on tirasemtiv  than on placebo (> 10% difference) were dizziness (50.8% 
vs. 19.7%), fatigue (33.2% vs. 14.2%), and nausea (21.9% vs. 7.8%).   
Patients on tirasemtiv  lost more weight than patients on placebo (change from baseline to 
Week 12: -1.70 kg vs. -0.79 kg; p = 0.006).  Weight loss was significantly greater in patients 

Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 17 with gastrointestinal AEs (e.g. , nausea and decreased appetite) on either treatment.  However, 
such AEs occurred more frequently on tirasemtiv  than on placebo (43.5% vs. 25.8%).   
The statistically significant effect to reduce the decline in vital capacity observed in CY [ADDRESS_541098].  The cardinal symptom of 
ALS that directly affects survival is weakness of the skeletal muscles necessary for respi[INVESTIGATOR_1516].  
Therefore, the significant reduction in the decline in vital capacity seen in this trial over 12 
weeks is cli nically relevant to patients with ALS.  Furthermore, the difference in vital capacity 
(measured by [CONTACT_428032]) between tirasemtiv  and placebo was maintained four weeks after 
discontinuation of double- blind treatment.  This suggests that  tirasemtiv  may have a durable 
impact on this measure of respi[INVESTIGATOR_352482].  These effects, if persistent over longer periods of time, suggest that tirasemtiv  may reduce progressive respi[INVESTIGATOR_428001] .  
1.4.3. Phase 3 Clinical Trial in Patients  with ALS (CY 4031; VITALITY- ALS) 
CY 4031, also known as VITALITY- ALS (Ventilatory  Investigation  of Tirasemtiv  and 
Assessments of Longitudindal I ndices after Treatment for a Year in ALS), is an ongoing Phase [ADDRESS_541099] skeletal muscle troponin activator,  tirasemtiv , in patients with 
ALS who can complete two weeks of treatment with open- label  tirasemtiv  (125 mg twice daily ).  
Both patients who are currently taking riluzole  and those who are not are enrolled in the study.  
Patients taking riluzole  randomized to tirasemtiv  have had their riluzole  dose decreased to 50 
mg/day (half the approved dose) in a double-blind fashion, since previous studies demonstrated that administration of tirasemtiv  approximately doubles the exposure to concomitant riluzole . 
CY 4031 includes th ree phases; an open-label phase, a double-blind, placebo-controlled phase, 
and a double-blind, placebo-controlled tirasemtiv  withdrawal phase.  
Following completion of two weeks of treatment with open- label tirasemtiv , patients are 
randomized 3:2:2:2 to placebo and three different dose levels of tirasemtiv .   
Approximately 600 patients are expected to be enrolled in the open- label phase.  Approximately 
477 of the patients enrolled onto open- label treatment are expected to be randomized in the 
double-blind, placebo-controlled phase.  
An independent Data Monitoring Committee ( DMC) has periodically assessed  patient safety in 
an unblinded manner during the course of the study and there have been no changes to study 
conduct.   
Study CY 4031 began enrollment in September 2015 and is currently ongoing.  Additional 
information about the study can be found at www.clinicaltrials.gov.
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 18 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened  
End = Last visit  
Healthy Male 
Volunteers 
Phase 1 
(CY 4011A) 
 57 • Double-blind, placebo -controlled; parallel 
dosing; tirasemtiv  vs. placebo 
• Determine safety, tolerability and PK of 
increasing single doses  
• Determine max imum tolerated dose (MTD) 
and plasma concentration • Single doses up to 2500  mg administered  
– Solid active pharmaceutical ingredient in capsule: 20 mg to 1250 mg 
– Liquid suspension: 640 mg to 2500 mg 
• MTD determined to be 2000 mg ; mean C max = 
29.24 µg/mL  
• Median Tmax 5.0 hr for both formulations 
• Terminal t1/2 averaged 12.2 and 11.5 hours for 
the solid and liquid formulation, respectively  
• Dose proportional increase in  AUCinf over the 
dose range of 20 to 2500 mg 
• tirasemtiv  was generally well tolerated; no SAEs  07 May 2009 to     
17 Feb 2010  
 
Healthy Male 
Volunteers 
Phase 1 
(CY 4011B) 12 • Double-blind, randomized, placebo-
controlled 
• 4-period, cross- over; single doses of 250, 
500, 1000 mg and placebo in random 
order 
• Assess pharmacodynamic (PD) effects  
• Relate any effects observed to associated 
plasma concentrations 
 • Statistically significant increases versus placebo in peak force generated by [CONTACT_428033] n frequency and to tirasemtiv 
dose and plasma concentration  
• Tirasemtiv was generally well tolerated; no SAEs 
 [ADDRESS_541100] 2009 to      
21 Dec 2009
 
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 19 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit 
Healthy Male 
Volunteers 
Phase 1 
(CY 4012) 24 • Double-blind, randomized, placebo-
controlled 
• Once daily dosing for 7 days  
• Two cohorts, parallel dosing:  
– tirasemtiv  250 mg vs. placebo 
– tirasemtiv  375 mg vs. placebo 
• After multiple doses to steady-state: 
– Assess safety and tolerability  
– Evaluate the PK profile  
 • Dose proportional C max and AUC 24hr 
• Modest (~70%) accumulation from single-dose 
to steady-state 
– Mean C max of 6.34 and 8.22 µg/mL  after 
single doses of 250 mg and 375 mg, 
respectively  
– Mean C max of 9.13 and 13.39 µ/mL  after 
dosing to steady-state with 250 mg QD and 
375 mg QD, respectively 
• Mean t 1/2 of 8.99 hr and 12.28 hr after dosing to 
steady-state with 250 mg QD and 375 mg QD, 
respectively  
• Systemic exposures were high; inter- subject 
variability was low  
• Tirasemtiv was generally well tolerated; no 
SAEs [ADDRESS_541101] 2009 to      
17 Dec 2009  
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 20 Table 4: Completed Phase 1 and Phase 2a Clinical Studi es with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit 
Healthy Male or 
Female Volunteers  
Phase 1 
(CY 4013) 
 
 39 Open-label, drug-drug interaction (DDI) and 
food effect study (2 part study)  
Part A  
• steady-state administration of tirasemtiv 
on the PK of single doses of riluzole 
Part B 
• steady-state administration of tirasemtiv 
on the PK of single doses of a warfarin + 
rosiglitazone cocktail  
• effect of food on a single dose of 
tirasemt iv 
• safety and tolerability of multiple doses of tirasemtiv  Part A  
• Steady-state tirasemtiv  (250 mg) raised the 
mean C max of riluzole approximately 
2.04-fold, mean AUC inf approximately 
3.77-fold compared with riluzole alone 
• Mean t 1/2 of riluzole increased f rom 7.52 
hours to 14.72 hours in the presence of steady-state tirasemtiv  
• Co-administration of tirasemtiv  reduced the 
inter-subject variability of riluzole C max and 
clearance  
Part B 
• Analysis of PK data from Part B of the study indicated that the AUC
inf for rosiglitazone 
and both S- warfarin and R -warfarin increased 
approximately 2-fold in the presence of steady-state plasma tirasemtiv  achieved by 
[CONTACT_428034] a dosage of 250 mg once daily  
• Food had no effect on t max, or AUC  
• Administration of a high -fat meal increased 
the Cmax of tirasemtiv by [CONTACT_3450] 55%  15 Mar 2011 to      
27 Jun 2011  
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 21 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End 
Start = First screened   
End = Last visit 
Patients with ALS  
Phase 2a 
(CY 4021) 67 • Double-blind, randomized, placebo-
controlled 
• 3-period, crossover study  
• Single doses of tirasemtiv (250 mg, 500 
mg) and placebo • Single doses of tirasemtiv were safe and 
generally well tolerated  
• Dizziness, which was generally mild, was the 
most frequently reported and most clearly 
dose-related adverse event  
• Both patients and investigators perceived a dose- and concentration-dependent 
improvement in the patients’ overall status at 6 hours after dosing  
• Statistically significant improvement in Maximum Voluntary Ventilation (MVV) at 6 and 24 hours after a single 500 mg dose; 
Sniff Nasal Inspi[INVESTIGATOR_13955] (SNIP) also 
trended to increase  
• Trend to increase in sub -maximum grip  
strength endurance  
• Small but statistically significant increases in Maximum Voluntary Isometric Contraction 
(MVIC) strength of some but not all muscles 
studied 29 Mar 2010 to       
2 Nov 2010
 
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 22 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened  
End = Last visit  
Patients with 
Claudication  
Phase 2a 
(CY 4022) 61 • Double-blind, randomized, placebo-
controlled  
• 3-period cross-over study  
• Single doses of tirasemtiv (375 mg, 750 mg) 
and placebo; the protocol was amended to 
reduce the 750 mg dose to 500 mg • Single doses of 375mg and 500 mg were safe 
and generally well tolerated  
• Two patients experienced SAEs including 
severe dizziness, prompting a protocol 
amendment to reduce the 750 mg dose to 500 mg   
• Statistically significant and dose -related 
increases in total calf muscle work assessed by 
[CONTACT_428035]  
• Statistically significant and dose -related 
decreases in [ADDRESS_541102]  
 28 May 2010 to     
31 Mar 2011  
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 23 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit 
Patients with ALS  
Phase 2a 
(CY 4024) 49 • Double-blind, randomized, placebo-
controlled study to evaluate the safety and 
tolerability of 14 days dosing of tirasemtiv  
without and with the concomitant administration of riluzole 
• 14 days of once daily  oral dosing with 
tirasemtiv  or placebo 
• Four parallel treatment groups 
– Placebo 
– tirasemtiv  125 mg 
– tirasemtiv  250 mg 
– tirasemtiv  375 mg 
• Part A (no riluzole): 7-day washout of 
riluzole followed by 14 days of tirasemtiv  
or placebo 
• Part B: All patients took riluzole 50 mg 
once daily for 7 days before and during the 14 days of double-blind, once daily tirasemtiv  or placebo • 49 patients treated  
– Placebo: 6 Part A, 7 Part B  
– tirasemtiv  125 mg: 6 Part A, 6 Part B  
– tirasemtiv  250 mg: 6 Part A, 6 Part B 
– tirasemtiv  375 mg: 6 Part A, 6 Part B 
• Tirasemtiv appeared to be safe and well 
tolerated at once daily  doses of 125 mg, 250 mg, 
and 375 mg daily for 14 days 
• Plasma concentrations of tirasemtiv  were 
unaffected by [CONTACT_3252] -administration with riluzole, 
while plasma concentrations of riluzole 
approximately doubled during co-administration with tirasemtiv  
• AEs and clinical outcome measures during 
treatment with tirasemtiv  appeared similar with 
or without co-administration of riluzole 50 mg daily 
• The most frequently reported adverse event was dizziness. Most epi[INVESTIGATOR_428002] 
• Encouraging trends to increase the ALS 
Functional Rating Scale -Revised score and 
MVV were observed  in patients treated with 
tirasemtiv  Part A:                   
20 Jun 2011 to      
10 Nov 2011  
Part B:                   
[ADDRESS_541103] 2011 to      02 Mar 2012  
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 24 Table 4: Completed  Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit 
Patients with ALS  
Phase 2a 
(CY 4025) 27 • Double-blind, randomized, placebo-
controlled s tudy to evaluate the safety and 
tolerability of 21 days dosing of tirasemtiv  
administered according to a twice-daily, 
dose titration regimen with the concomitant administration of riluzole
 
• 21 days of twice daily oral dosing with 
tirasemtiv  or placebo 
• Two parallel treatment groups  
– Placebo dose titration  
− Week 1: 1 tablet twice daily  
− Week 2: 1 tablet in the 
morning and 2 tablets in the 
evening 
− Week 3: 2 tablets twice daily  
– Tirasemtiv dose titration  
− Week 1: 125 mg twice daily  
− Week 2: 125 mg in the morning and 250 mg in the 
evening 
− Week 3: 250 mg twice daily  
• All patients took riluzole 50 mg once daily 
for 7 days before and during the 21 days of 
double-blind, twice -daily dose titration with 
tirasemtiv  or placebo  • 27 patients treated   
– Placebo titration: 6  
– tirasemtiv  titration: 21  
• Tirasemtiv administered in the twice -daily, dose 
titration regimen studied appeared to be safe and well tolerated  
• 14 of 21 patients randomized to tirasemtiv  were 
titrated to tirasemtiv 250 mg twice daily and 
completed the study at that dose level 
• Dizziness was the most frequent adverse event, 
reported by 12 of 21 patients on tirasemtiv  
– Mild in 10 patients , moderate in 2 patients  
– Resolved during continued dosing in 6 
patients 
• Encouraging trends to increase the ALS 
Functional Rating Scale- Revised score and 
MVV were observed  in patients treated with 
tirasemtiv  18 Nov 2011 to     
16 Mar 2012  
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 25 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit 
Patients with 
Myasthenia Gravis  
Phase 2a 
(CY 4023) 32 • Double-blind, randomized, placebo-
controlled 
• 3-period cross-over study  
• Single doses of tirasemtiv (250 mg, 500 
mg) and placebo  
 • Single doses of tirasemtiv were safe and 
generally well tolerated  
• Dizziness, which was generally mild, was the 
most commonly reported adverse event  
• There were no premature terminations and no 
SAEs reported  
• Quantitative Myasthenia Gravis (QMG) 
score decreased in a dose- related fashion  
• Forced Vital Capacity (FVC) increased 
versus placebo at [ADDRESS_541104] 2012 
 
  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 26 Table 5: Completed Phase 2b Clinical Studies with Tirasemtiv  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened  
End = Last visit  
Patients with ALS 
BENEFIT -ALS 
Phase 2b,  
(CY 4026) 
 711 • Double-blind, randomized (1:1), placebo-
controlled study to evaluate the safety and 
tolerability of 12  weeks of 250 -500 mg 
tirasemtiv administered according to a twice 
daily dose titration regimen  
– Open-label period: following screening 
and confirmation of eligibility, patients 
are enrolled in the study and receive 125 
mg tirasemtiv twice daily for 1  week 
– Dose-titration period: p atients 
randomized to tirasemtiv  or placebo and 
are titrated to their MTD with a target dose of 250 mg BID over 3 weeks 
– MTD period: patients maintained at their 
MTD for 9  weeks 
• Patients randomized to tirasemtiv who were 
taking riluzole had a blinded dose reduction to 50 mg once daily 
• Primary objective: assess effect of tirasemtiv  on ALSFRS- R total score
 
• Secondary objectives: alternate assessments of effect on change from baseline in ALFRS-R and effect on respi[INVESTIGATOR_428003]:  
• Tirasemtiv had no impact on changes from 
baseline in ALSFRS- R total score compared 
with placebo  
• Compared with placebo, treatment with 
tirasemtiv  showed a statistically significant 
reduction in the decline in SVC, no impact on MVV, and a mixed effect on SNIP, with no effect on the rate of decline, but a statistically 
significantly greater decrea se at the end of 
Weeks 4 and 12  
• Treatment with tirasemtiv  had no effect on 
handgrip fatigue and a mixed effect on mus cle 
strength mega -score, with a significantly slower 
rate of decline, but no statistical differ ence at 
any measured time point  
The safety and tolerability assessments obtained 
during the study showed:  
• A greater proportion of patients treated with tirasemt iv had AEs and AEs leading to 
discontinuation from the study than patients treated with placebo  
• Commonly reported AEs with tirasemtiv 
treatment were dizziness, fatigue, and nausea; all were reported more frequently with tirasemtiv  
than placebo  [ADDRESS_541105] 2012 to       
21 Mar 2014 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 27 Table 5: Completed Phase 2b Clinical Studies with Tirasemtiv  (Continued)  
   • Patients treated with tirasemtiv  experienced 
dizziness sooner than patients treated with 
placebo, and the duration of the dizziness epi[INVESTIGATOR_428004]  
• Patients treated with tirasemtiv  lost more weight 
than those treated with placebo; weight loss appeared to be associated with gastrointestinal AEs 
• Laboratory parameters, vital signs, and ECG 
intervals were stable over the course of the study   
 
  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 28 Table 6: Ongoing Phase 3 Clinical Study  with Tirasemtiv  
Population  
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit  
Patients with ALS  
VITALITY -ALS 
Phase 3 
(CY 4031) 600 • Multi-national, double-blind, randomized, 
placebo-controlled, stratified, parallel 
group, study with tirasemtiv  treatment up 
to 52 weeks in ALS 
• Only those patient s who tolerated two 
weeks of open- label tirasemtiv  (125 mg 
BID), are randomized to the blinded phase  
• Patients randomized 3:2:2:2 to placebo and three total daily dose levels of tirasemtiv 
(250, 375 and 500 mg) for [ADDRESS_541106] 6 weeks
 
• Following the 48 weeks, patients on tirasemtiv  are re-randomized 1:1 to either 
their same dose of tirasemtiv  or to placebo  
for the next 4 weeks (to Week 52) . Patients 
originally randomized to placebo w ill 
continue to receive placebo  
• After completion of study drug, there is a final follow -up visit at Week 56  Study Ongoing 28 Aug 2015 
Ongoing
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 29 2. STUDY OBJECTIVES  
2.1. Primary Objective  
The primary objective is to assess the  long-term safety and tolerability of tirasemtiv , in patients 
with ALS .   
2.1.1. Primary Endpoint  
The primary endpoint is the incidence of adverse events (AEs) in the patient population.  
2.2. Secondary Objectives  
The secondary objectives are: 
• To compare the clinical course of patients who completed treatment with tirasemtiv  in 
CY 4031 with those who completed treatment with placebo in CY 4031 during 
continued treatment of both groups with tirasemtiv  during CY 4033 
• To compare the clinical course of patients who completed treatment with tirasemtiv  in 
CY 4031 during that study with their clinical course during continued treatment with 
tirasemtiv  during CY 4033 
• To compare the clinical course of patients who completed treatment with placebo  in 
CY 4031 during that study with their clinical course during treatment with tirasemtiv  
during CY 4033 
2.2.1. Secondary Endpoints  
The secondary endpoints are:  
• Time to first u se of assisted ventilation or death 
• Time to the first occurrence of respi[INVESTIGATOR_5448] (defined as tracheostomy or 
the use of non-invasive ventilation for ≥22 hours per day for ≥10 consecutive days) or 
death 
• Time to death  
• Decline in percent predicted SVC from baseline 
• Decline in ALSFRS -R score from baseline 
• Slope of the change from baseline in percent predicted SVC  
• Slope of the change from baseline in ALSFRS-R 
The time to event endpoints will be assessed from the start of CY [ADDRESS_541107] 48 weeks of either CY 
4031 or CY 4033. 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 30 See Section [IP_ADDRESS] for detailed descriptions of the secondary endpoint measures and their 
analyses.   
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541108] skeletal muscle troponin 
activator,  tirasemtiv , in patients with ALS who finished double- blind study drug and completed 
participation (through Week 56) in the CY 4031 study ( VITALITY -ALS).  Approximately 
350 patients from the sites that partic ipated in CY 4031 study are expected to be enrolled in the 
open-label extension study, CY 4033. 
Following enrollment, patients will begin dosing of tirasemtiv  125 mg twice daily (250 mg/day) 
for a period of 4 weeks and will titrate to their tolerated dose , the maximum dose being 250 mg 
twice daily (500 mg/day) ( Table 7).  The Principal Investigator (PI) , or designee with 
prescriptive authority in their local jurisdiction, may decide to up-titrate, maintain dose, or down-
titrate the patient to the previously tolerated dose of tirasemtiv .  Please see Section 6.3 for further 
guidance on dos e adjustment . 
Table 7: Study Dosing Plan 
Initial Dose 
(Day 1 Clinic Visit) Planned Up-Titration  
(Week 4 Clinic Visit)  Planned Up-Titration  
(Week 6 Phone Call) 
[ADDRESS_541109] dose: 1 tablet (125 mg) of 
tirasemtiv   
Second dose: 1 tablet (125 mg) of tirasemtiv   
(approximately 12 hours apart) [ADDRESS_541110] dose: 1 tablet (125 mg) of tirasemtiv   
Second dose: 2 tablets (250 mg) of tirasemtiv  
(approximately 12 hours apart) [ADDRESS_541111] dose: 2 tablets (250 mg) of 
tirasemtiv  
Second dose: 2 tablets (250 mg) 
of tirasemtiv  
(approximately 12 hours apart) 
  
Patient clinic visits will occur at Day 1, Week 4, Week 8, Week 12, Week 24, Week 36, 
Week 48, and every 12 w eeks thereafter.  P atients will be contact[CONTACT_428036] 2, Week 6, and Week 10. If a patient decides to discontinue tirasemtiv , the 
patient will come into the clinic for the Tirasemtiv  Discontinuation Visit and the 28 Day Safety 
Follow-up Visit if the patient is  able; otherwise the patient wi ll be contact[CONTACT_428037] (Table 3). 
 
Figure 3: Study Visit Diagram 
 

Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 32 3.1. Tirasemtiv  Dose Rationale  in the Open Label Extension Study 
In the Phase 3 study of tirasemtiv  in patients with ALS, CY 4031 ( VITALITY -ALS), following a 
2 week open -label run-in period at 250 mg/day, patients were randomized 3:2:2:2 to placebo and 
three different maximum dose levels of tirasemtiv , 250 mg/day (125 mg twice daily ), 
375 mg/day (1 25 mg in the morning and 250 mg in the evening), and 500 mg/day (250 mg twice 
daily). 
In CY 4031, for patients randomized to 500 mg/day, the initiation and titration of dosing was 
done as follows: 
• Open label treatment for 2 weeks at 250 mg/day (125 mg twic e daily) 
• Following randomization, treatment for another 2 weeks at 250 mg/day (125 mg 
twice daily)  
• If well tolerated, up-titration to 375 mg/day (125 mg in the morning and  250 mg in 
the evening)  for 2 weeks  
• If well tolerated, up- titration to the final dose  of 500 mg/day (250 mg twice daily) 
In this open label extension study, the maximum dose level for all patients will be 500 mg/day.  
Initiation and titration of dosing will follow the same schedule employed in CY 4031 as follows: 
• Treatment for 4 weeks at 2 50 mg/day (125 mg twice daily) 
• If well tolerated, up-titration to 375 mg/day (125 mg in the morning and 250 mg in 
the evening) for 2 weeks 
• If well tolerated, up-titration to the final dose of 500 mg/day (250 mg twice daily) 
It is important to note that p atients will not escalate their dose if signs of intolerability are 
present.  Patients who do not tolerate a dose escalation due to symptoms believed to be due to 
treatment with study drug will be returned to a previously tolerated dose level.   
To date, the DMC has not asked for any change in the study conduct of CY 4031, thus the 500 mg/day dose is being employed in this study as it may maximize efficacy and will maximize the 
evaluation of the safety and tolerability  of tirasemtiv . 
3.2. Riluzole Dose Adjustment Rationale  
Tirasemtiv  is a mechanism -based inhibitor of the drug metabolizing enzyme CYP1A2, the major 
pathway of elimination for riluzole; consequently, when tirasemtiv  is administered 
concomitantly with riluzole, plasma riluzole concentrations are increas ed relative to when 
riluzole is administered in the absence of tirasemtiv .  In CY 4031, patients taking riluzole who 
were randomized to double-blind tirasemtiv  had their riluzole dose decreased from 50 mg twice 
daily to 50 mg once daily in a double-blind manner.   
In the current study, CY 4033, all patients will be taking tirasemtiv .  Thus, patients also taking 
riluzole will be advised to skip their evening dose of riluzole.  Patients who take riluzole will use 
their own supply of riluzole (described in Section 5.16, Concomitant Medications). 
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 33 4. STUDY POPULATION  
Approximately 350 patients who fulfill the eligibility  criteria will be enrolled in the study.  
4.1. Inclusion Criteria 
1. Able to comprehend and willing to sign an  Informed Consent Form (ICF) . If verbal 
consent is given, a Legal Designee of the patient must sign the ICF form 
2. Completed participation on study drug and the Follow- Up Visit in the CY [ADDRESS_541112] 
agree for the duration of their participation in the study to either:  
a. Use a condom during sexual intercourse with female partners who are of childbearing 
potential (i.e., following menarche until post-menopausal if not anatomically and physiologically incapable of becoming pregnant) AND to have female partners use a highly effective means of contraception ( see below ): 
OR 
b. Abstain from sexual intercourse during participation in the study. 
4. Female patients  who are not post-menopausal (≥ 1 year) or sterilized, must: 
a. Not be breastfeeding  
b. Have a negative pregnancy test  
c. Have no intention to become pregnant during participation in the study, 
AND  
d. Practice sexual abstinence, defined as refraining from intercourse during the d uration 
of the study OR if male partners are not vasectomized with a confirmed zero sperm 
count, require use of a condom AND use of a highly effective contraceptive measure, 
for the duration of the study such as:  
− Combined (estrogen and progestogen containing) oral, intravaginal, or 
transdermal hormonal contraception associated with inhibition of ovulation 
− Progestogen -only oral, injectable, or implantable hormonal contraception 
associated with inhibition of ovulation 
− Intrauterine device (IUD)  
− Intrauterine hormone- releasing system (IUS)  
− Bilateral tubal occlusion  
4.2. Exclusion Criteria  
1. Has a diaphragm pacing system (DPS) at study entry or anticipate DPS placement during the course of the study 
2. Has taken any investigational study drug (other than tirasemtiv ) prior to dosing, within 30 
days or five half-lives of the prior agent, whichever is greater  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 34 3. Use of tizanidine and theophylline-containing medications during study participation 
4. Participation or planning to participate in another clinical trial involving stem cell  therapy 
for the treatment of ALS or another investigational drug  
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 35 5. STUDY PROCEDURES  
5.1. Day 1 Clinic Visit  
The Day 1 Clinic V isit for CY 4033 may  be the same day as the Follow-Up Visit ( Week 56) for 
the CY 4031 ( VITALITY -ALS) study. A signed ICF for the CY [ADDRESS_541113] be obtained 
prior to any study procedures for the Follow-Up Visit ( Week 56) for CY 4031 and before 
CY 4033 study specific assessments are initiated. In the event that a patient i s unable to 
physically sign an ICF but is able to provide verbal consent, a Legal Designee of the patient can 
sign on the patient’ s behalf.  
The following are done as part of the Follow-Up V isit for CY  [ADDRESS_541114] to take riluzole, should be 
instructed to take only half of their dose of riluzole during their participation in CY  4033:  
1. Clinical safety laboratory evaluations including a serum chemistry panel, complete blood 
count (CBC), urinalysis, creatine phosphokinase (CPK) * Please note that Safety Lab 
results are not prohibitory to the start of dosing.  
2. Vital signs including weight  
3. Slow Vital Capacity (SVC)  
4. ALSFRS-R 
5. Physical examination  
6. Adverse Event Evaluation  
7. Concomitant medication assessment  
8. Suicidality assessment  
In addition, these assessments  are mandatory prior to administration of tirasemtiv  in CY 4033: 
1. Informed consent documentation 
2. Inclusion/exclusion criteria evaluation  
3. Demograp hic data collection  
4. Serum pregnancy test for females of child bearing potential  
Once all pre- dose procedures have been performed at the Day [ADDRESS_541115] the date and time of twice daily tirasemtiv  administration . 
Patients will be given an adequate supply of tirasemtiv  to take twice daily for  four weeks at 
home until their next clinic visit ( Week 4 Clinic Visit).   
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 36 5.2. Week 2 Phone Call  
Patients will be contact[CONTACT_428038] 2 Phone Call  
to assess tolerability, adverse events, and any changes to concomitant medications .   
Patients will continue tirasemtiv  dosing until the Week 4 Clinic Visit. 
5.3. Week 4 Clinic Visit  
Patients will return to the study site for the Week 4  Clinic Visit. Patients will be instructed not to 
take their dose of tirasemtiv  prior to arrival at the study site.  
The following assessments will be performed prior to administration of tirasemtiv  while in the 
clinic: 
1. Clinical Safety Labs  
2. Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428005], and temper ature) as well as body weight (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted) 
3. SVC   
4. ALSFRS-R 
5. AE evaluation  
6. Concomitant medication assessment since last visit 
7. Suicidality assessment  
If patients are tolerating tirasemtiv , they may be up- titrated to 375  mg/day; if not, patients should 
be maintained at their current dose level.  
Once all pre- dose procedures have been performed at the Week [ADDRESS_541116] the date and time of 
twice daily tirasemtiv  administration . Patients will be given an adequate supply of tirasemtiv  to 
take twice daily for 4 weeks at home until their next clinic visit, Week 8  Clinic Visit. 
5.4. Week 6 Phone Call  
Patients will be contact[CONTACT_205903] [INVESTIGATOR_428006] , 
approximately 2 weeks later for the Week 6  Phone Call to assess tolerability, adverse events, and 
any changes to concomitant medications .  The PI [INVESTIGATOR_428007] -titrate patients .  Patients will either continue 
at their current dose of tirasemtiv  or, if previously up- titrated at the Week  4 Clinic Visit and 
continue to tolerat e tirasemtiv , patients will be up titrated to 500 mg /day.  
Patients will continue tirasemtiv  dosing as advised until the Week 8 Clinic Visit. 
5.5. Week 8 Clinic Visit 
Patients will return to the study site for the Week 8  Clinic Visit. Patients will be instructed not to 
take their dose of tirasemtiv  prior to arrival at the study site.  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 37 The following assessments will be performed prior to administration of tirasemtiv  while in the 
clinic: 
1. Clinical Safety Labs  
2. Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428005], and temperature) as well as body weight (if the patient has lost 
≥ 5% of body weig ht since baseline, the Investigator will be alerted)  
3. SVC  
4. ALSFRS-R 
5. AE evaluation  
6. Concomitant medication assessment since last visit 
7. Suicidality assessment  
Once all pre- dose procedures have been performed at the Week [ADDRESS_541117] the date and time of twice daily tirasemtiv  administration .  Patients will be given an adequate supply of tirasemtiv  to 
take twice daily for 4 weeks at home until their next clinic visit, Week 12 Clinic Visit.   
5.6. Week 10 Phone Call  
Patients will be contact[CONTACT_428039] 2 weeks later for the Week 10  Phone Call 
to assess tol erability, adverse events, and any changes to concomitant medications .   
Patients will continue tirasemtiv  dosing until the Week 12 Clinic Visit. 
5.7. Week 12 Clinic Visit  
Patients will return to the study site for the Week 12  Clinic Visit. Patients will be ins tructed not 
to take their dose of tirasemtiv  prior to arrival at the study site.  
The following assessments will be performed prior to administration of tirasemtiv  while in the 
clinic: 
1. Clinical Safety Labs  
2. PK sampling  
3. Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428005], and temperature) as well as body weight (if the patient has lost ≥ 5% of body weight since baseline, the Investigator will be alerted) 
4. SVC   
5. ALSFRS-R 
6. AE evaluation  
7. Concomitant medication assessment since last visit 
8. Suicidality assessment  
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541118] the date and time of 
twice daily tirasemtiv  administration . Patients will be given an adequate supply of tirasemtiv  to 
take twice daily for 12 weeks at home until their next clinic visit, Week 24 Clinic Visit.   
5.8. Week 24 Clinic Visit  
Patients will return to the study site for the Week 24  Clinic Visit. Patients will be instructed not 
to take their dose of tirasemtiv  prior to arrival at the study site.  
The following assessments will be performed prior to administration of tirasemtiv  while in the 
clinic: 
1. Clinical Safety Labs  
2. Serum pregnancy test for females of child bearing potential  
3. PK sampling  
4. Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428005], and temperature) as well as body weight (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted) 
5. SVC   
6. ALSFRS-R 
7. AE evaluation  
8. Concomitant medication assessment since last visit 
9. Suicidality assessment  
Once all pre- dose procedures have been performed at the Week [ADDRESS_541119] the date and time of twice daily tirasemtiv  administration . Patients will be given an adequate supply of tirasemtiv  to 
take twice daily for 12 weeks at home until their next clinic visit, Week 36 Clinic Visit.   
5.9. Week 36 Clinic V isit 
Patients will return to the study site for the Week 36  Clinic Visit. Patients will be instructed not 
to take their dose of tirasemtiv  prior to arrival at the study site.  
The following assessments will be performed prior to administration of tirasemtiv  while in the 
clinic: 
1. Clinical Safety Labs  
2. Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428005], and temperature) as well as body weight (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted) 
3. SVC   
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541120] the date and time of 
twice daily tirasemtiv  administration . Patients will be given an adequate supply of tirasemtiv  to 
take twice daily for 12 weeks at home until their next clinic visit, Week 48 Clinic Visit.   
5.10. Week 48 Clinic Visit  
Patients will return to the study site for the Week 48  Clinic Visit. Patients will be instructed not 
to take their dose of tirasemtiv  prior to arrival at the study site.  
The following assessments will be performed prior to administratio n of tirasemtiv  while in the 
clinic: 
1. Clinical Safety Labs  
2. Serum pregnancy test for females of child bearing potential  
3. PK sampling  
4. Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428005], and temp erature) as well as body weight (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted) 
5. SVC   
6. ALSFRS-R 
7. AE evaluation  
8. Concomitant medication assessment since last visit 
9. Suicidality assessment  
Once all pre- dose procedures have been performed at the Week [ADDRESS_541121] the date and time of 
twice daily tirasemtiv  administration . Patients will be given an adequate supply of tirasemtiv  to 
take twice daily for 12 weeks at home until their next clinic visit.   
5.11. Ongoing Clinic Visits Every 12 Weeks 
Patients will return to the study site every 12 weeks. Patients will be instructed not to take their 
dose of tirasemtiv  prior to arrival at the study site.  
The following assessments will be performed prior to administration of tirasemtiv  while in the 
clinic: 
1. Clinical Safety Labs  
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541122] for females of child bearing potential (every 24 weeks)  
3. PK sampling  (every 24 weeks)  
4. Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428008], and temperature) as well as body weight (if the 
patient has lost ≥ 5% of body weight since baseline, the Investigator will be alerted) 
5. SVC 
6. ALSFRS-R 
7. AE evaluation  
8. Concomitant medication assessment since last visit 
9. Suicidality assessment  
Once all pre- dose procedures have been performed at the Ongoing Clinic Visit Every [ADDRESS_541123] a phone visit if transport is not possible. If a patient  is able to come in for a clinic visit, 
the following assessments  will be conducted: 
1. Clinical Safety Labs  
2. Serum pregnancy test for females of child bearing potential  
3. PK Sampling  
4. Vital Signs  
5. SVC 
6. ALSFRS-R 
7. AE evaluation  
8. Concomitant medication assessment since last visit 
9. Inquire about use of non-invasive ventilation, if so collect how many hours a day 
10. Inquire if patient has had a tracheostomy  
11. Assessment of Suicidality  
If a patient  is unable to come in for a clinic visit, the following assessments will be conducted  
via a phone call: 
1. Survival status 
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541124] how many hours a day 
6. Inquire if patient has had a tracheostomy  
7. Assessment of Suicidality  
5.13. 28 Day Safety Follow-Up Visit  
Patients who are able to return to the clinic for the 28 Day Safety Follow- Up Visit in person will 
undergo the following assessments: 
1. Clinical Safety Labs  
2. Vital Signs  
3. SVC 
4. ALSFRS-R 
5. AE evaluation  
6. Concomitant medication assessment since last visit 
7. Inquire about use of non-invasive ventilation, if so collect how many hours a day 
8. Inquire if patient has had a tracheostomy  
9. Assessment of Suicidality  
If a patient  is unable to come in for a clinic visit, the following assessments will be conducted 
via a phone call: 
1. Survival status 
2. ALSFRS-R 
3. AE evaluation  
4. Concomitant medication assessment since last visit 
5. Inquire about use of non-invasive ventilation, if so collect how many hours a day 
6. Inquire if patient has had a tracheostomy  
7. Assessment of Suicidality  
5.14. Visit Windows  
To aid in scheduling patient visits, the following study visit windows are considered acceptable 
(Table 8).  If a patient visit must be scheduled outside the visit window, the Medical Monitor 
should be contact[INVESTIGATOR_530]. Please note that the Week 6 Phone Call needs to be conducted by [CONTACT_978] [INVESTIGATOR_428009] . 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 42 Table 8: Visit Windows  
Visit Visit Window  
Day 1 Clinic Week 56 of CY 4031/First day of Dosing  CY 4033 
Week 2 Call 2 Weeks after the Day 1 Visit  ± 2 days 
Week 4 Clinic 4 Weeks after the Day 1 Visit ± 2 days 
Week 6 Call 6 Weeks after the Day 1 Visit ± 2 days 
Week 8 Clinic 8 Weeks after the Day 1 Visit ± 2 days 
Week 10 Call 10 Weeks after the Day 1 Visit ± 2 days 
Week 12 Clinic 12 Weeks after the Day 1 Visit  ± 2 days 
Week 24 Clinic 24 Weeks after the Day 1 Visit ± 7 days 
Week 36 Clinic  36 Weeks after the Day 1 Visit ± 7 days 
Week 48 Clinic 48 Weeks after the Day 1 Visit ± [ADDRESS_541125] visit  ± 7 days 
Tirasemtiv  Discontinuation Visit  To occur as soon as possible after patient Discontinues Tirasemtiv  use 
28 Day Safety Follow -up Visit 28 days after the Tirasemtiv  Discontinuation date +5 days 
5.15. Timing o f Doses 
Tirasemtiv  should be taken twice daily  (except on clinic visit days where it should be taken in the 
clinic), approximately 12 hours apart.  Tirasemtiv  should be taken ≥ 2 hours after a meal or 1 
hour prior to a meal. 
5.16. Concomitant Medications  
All prescription drugs, over-the-counter medications, nutriceuticals and herbal remedies taken by 
[CONTACT_428040] 1 visit through the 28 Day S afety Follow-up visit should be 
entered into the electronic case report form  (eCRF). 
Patients who are currently  taking riluzole  at study entry  should reduce their dose to 50 mg once 
daily while taking tirasemtiv  in the open-label extension study. Patients who choose to take 
riluzole will use their personal supply. For patients taking riluzole, tirasemtiv  may be taken at the 
same time as riluzole.  
Tirasemtiv  inhibits multiple CYP450 isoforms (1A2, 2B6, 2C8, 2C9, and 2C 19).  Consequently, 
exposure to drugs primarily metabolized by [CONTACT_428041] .  Therefore, close attention should be paid to potential 
AEs related to their administration.  For example, blood pressure should be closely monitored for 
hypertensive patients taking angiotensin II receptor blockers metabolized by [CONTACT_097] 2C9, su ch as 
losartan and irbesartan. Diabetic patients taking oral anti -diabetic agents metabolized by 
[CONTACT_097] 2C8 or 2C9, including glyburide, glibencilamide, glipi[INVESTIGATOR_7130], glimepride and tolbutamide, 
should be cautioned to be aware of signs and symptoms of hypoglycemia, and serum glucose 
should be monitored as clinically appropriate.  Finally, caution should be exercised in the 
initiation of warfarin (also metabolized by [CONTACT_097] 2C9) if required during the study for the 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 43 treatment of thromboses or thromboembolic events, with careful monitoring of prothrombin 
times and/or international normalized ratio ( INR).  A list of currently approved drugs 
metabolized by [CONTACT_097] 2B6, 2C8, 2C9, and 2C19 may be found in Appendix B . 
Patients must refrain from taking theophylline  or tizanidine , which are primarily metabolized by 
[CONTACT_097] 1A2 (see Section  1.3), during their participation in the study.  Additionally, patients should 
be advised to avoid or use cautio n when taking medications or ingesting other substances that are 
metabolized by [CONTACT_097] 1A2, such as fluvoxamine, because their metabolism is inhibited by [CONTACT_428042] , so co-administration with tirasemtiv  will increase exposure to these compounds. 
Other medicat ions that inhibit or induce the activity of CYP 1A2 may  increase or decrease, 
respectively, exposure to riluzole  which is metabolized by [CONTACT_097] 1A2.  Consequently, these drugs 
should be avoided by [CONTACT_428043] .  A list of currently approved drugs that interact 
with CYP 1A2 is found in Appendix C . 
5.17. PK Sample Collection   
Blood samples for PK analysis of tirasemtiv , and its acid metabolite,  CK-2018595 will be 
collected at the time points listed in  Table 9. For each clinic visit, patients will be instructed 
NOT to take their next dose of tirasemtiv  until after the pre-dose PK blood draw.  
Table 9: Pharmacokinetic (PK) Samples  
Visit Sample Time Points  
Week 12 Pre-dose 
Week 24 Pre-dose 
Week 48 Pre-dose 
Every 24 Weeks Ongoing Pre-dose 
PK plasma samples remaining after completion of bioanalysis may also be used for exploratory 
analysis of tirasemtiv  metabolites.   These samples will NOT be used for pharmacogenomic or 
other testing.  
5.18. Clinical Safety Assessments  
5.18.1. Clinical Laboratory Evaluations 
Clinical safety laboratory evaluations (serum chemistry panel, CBC, UA,  and CPK) will be 
collected at Day 1, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, and every [ADDRESS_541126] for 
females of child bearing potential  will be collected at the Day 1 Clinic Visit, the Week 24 Clinic 
Visit, every 24 weeks thereafter  and at the Tirasemtiv  Discontinuation Visit.  
5.18.2. Vital Signs  
Vital signs measurements (including blood pressure, pulse, respi[INVESTIGATOR_428010] , and temperature ) as well as body weight  will be recorded at all clinic  visits. 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 44 5.18.3. Suicidality  Assessment  
The suicidality assessment (Beck Depression Inventory- Fast Screen) will be assessed as 
described in the study manual for all clinic visits , including the Tirasemtiv  Discontinuation Visit, 
and the 28 Day Safety Follow- Up Visit. 
5.19. Clinical and Pharmacodynamic Outcome Measures  
5.19.1. ALS Functional Rating Scale -Revised (ALSFRS -R)  
The ALSFRS -R will be administered as described in the stu dy manual for the following visits; 
Day 1, Week 4, Week 8, Week  12, Week 24, Week 36, Week 48, ongoing every 12 weeks, 
Tirasemtiv  Discontinuation Visit, and the 28 Day Safety Follow- Up Visit.  When a patient does 
not present in person for a scheduled visit, every attempt should be made to obtain the 
ALSFRS-R score by [CONTACT_428044]. 
5.19.2. Slow Vital Capacity (SVC) 
SVC will be performed as described in the study manual at every study clinic visit; Day 1, Week 
4, Week 8, Week 12, Week 24, Week 48, e very 12 weeks ongoing, and if the patient returns to 
the Clinic for the Tirasemtiv  Discontinuation Visit.  
5.20. Patient Discontinuation from Study Participation  
Patients will be informed that they are free to withdraw from the study at any time and for any 
reason. The Investigator may remove a patient from the study at any time if, in the Investigator's 
opi[INVESTIGATOR_1649], it is not in the best interest of the patient to continue in the study. For those patients who 
will not return to the study center for further study scheduled assessments, the Tirasemtiv  
Discontinuation Visit and 28 Day Safety Follow-Up Visit study assessments should be performed via phone whenever possible and documented. Notification of discontinuation will immediately be made to the Sponsor’s Medical Monitor. 
In all cases, for patients who discontinue tirasemtiv , the Investigator should discuss with the 
patient the option of continuing in the study to allow for once every 12 weeks telephone calls to 
assess vital status, NIV use, and/or ALSFRS- R rather than wit hdrawal from the study.  The level 
of follow up that is agreed to by [CONTACT_102] (eg, by [CONTACT_756]/mail, through family/friends, in correspondence/communication with other physicians, from review of the medical records) should be documented by [CONTACT_737].  
The date the patient is withdrawn from tirasemtiv  treatment or study participation and the reason(s) 
for discontinuation will be recorded on the patient’s eCRF. See Section 7.5.1 regarding follow-up 
of AEs (both non-serious and serious) continuing at the time of study discontinuation.   
5.21. Study Discontinuation  
An Investigator may discontinue the participation of his/her study site, or the entire study may be discontinued at the discretion of the Sponsor, based on the occurrence of the following: 
• AEs  
• Medical or ethical reasons affecting the continued performance of the study  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 45 • Cancellation of the development of tirasemtiv  for the potential treatment of ALS  
• Commercial availability  of tirasemtiv  in a given patient’s jurisdiction  
• When fewer than 20% of patients who began open- label treatment with tirasemtiv  in 
CY 4033 remain active in CY 4033 (*When [or if] this situation occurs, those 
patients who remain on treatment with tirasemtiv  in CY 4033 will continue to recei ve 
tirasemtiv  under circumstances compliant with the laws and regulations of their local 
jurisdictions; however, they will no longer be participants in the CY 4033 protocol) 
5.22. Safety Monitoring and Stoppi[INVESTIGATOR_428011]’s Medical Monitor , or designee,  in a blinded manner on a periodic basis: 
1. SAEs thought by [CONTACT_428045]  
2. Withdrawals due to AEs  (both serious and non-serious) 
3. Grade 3 or 4 (according to Common Terminology Criteria for Adverse Events [ CTCAE 
version 4.0], see Section 7.2) non-serious AEs  thought by [CONTACT_428046]  
4. Any death thought by [CONTACT_428047] P rincipal Investigator (PI) to be related to 
tirasemtiv  will result in stoppi[INVESTIGATOR_428012] a review.   
5. This review may result in  any of the following:  
• Discontinuation of the study 
• Discontinuation of enrollment at the affected and higher dose levels 
• Modification to study conduct 
• No change to the conduct of the study (if AEs  are determined to have been unrelated 
to tirasemtiv  administration)  
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541127]  
CK-2017357 (tirasemtiv ) investigational product is supplied as immediate release , white, 
modified oval tablets at a dose strength of 125 mg of tirasemtiv  per tablet , which are to be stored 
under secure conditions, a s specified in  the Investigator’s Brochure.  CK -2017357 t ablets contain 
125 mg of tirasemtiv  plus excipi[INVESTIGATOR_840] .   
Table 10: Tirasemtiv  Investigational Product 
Study Drug  CK-2017357 
Form Tablet 
Supplier Cytokinetics, Inc. 
Manufacturer  Patheon, Inc. 
CK-2017357 ( tirasemtiv ) tablets will be supplied to the clinical site in  induction sealed [ADDRESS_541128] of the receipt of tirasemtiv  as shipped by [CONTACT_1034] 
(or designee).  One copy of this receipt will be returned to the Sponsor when the contents of the tirasemtiv  shipment have been verified.  In addition, an accurate drug disposition record will be 
kept, specifying the lot number provided to each patient and the dates of dose administration.  
This drug accountability record will be available for inspection at any time.  At the completion of 
the study, the original drug accountability record will be available for review by [CONTACT_117605]. 
6.2. Dose Administration of Tirasemtiv  
Tirasemtiv  will be administered orally as tablets  (125 mg per tablet)  to patients with A LS.  Doses 
of tirasemtiv  will be dispensed in accordance with the study dosing plan ( Table 7). 
In this open label extension study with  tirasemtiv , the maximum dose level for all patients will 
be 500 mg/day.  Initiation and titration of dosing will use the following schedule: 
• Treatment for 4 weeks at 250 mg/day (125 mg twice daily) 
• If tolerated, up-titration to 375 mg/day ([ADDRESS_541129] dose  and 250 mg second dose ) 
for 2 weeks 
• If tolerated, up- titration to the final do se of 500 mg/day (250 mg twice daily) 
6.3. Dose Adjustment Criteria 
Patients who do not tolerate a dose escalation due to symptoms believed to be due to treatment with tirasemtiv  may be returned to a previously tolerated dose at the discretion of the 
Investigat or, or designee with prescriptive authority in their local jurisdiction.  No upward dose 
adjustments will be allowed subsequent to a dose reduction.  
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541130] of the receipt of tirasemtiv  as shipped by [CONTACT_1034] 
(or designee), including the kit number and date received.  One copy of thi s receipt will be 
returned to the Sponsor when the content of the investigational drug shipment has been verified . 
At the completion of the study, the original tirasemtiv  accountability record will be available for 
review by [CONTACT_117605]. 
All unused tirasemtiv  supplies will be returned to the Sponsor (or designee) for destruction per 
facility standard operating procedure ( SOP) or disposed of by [CONTACT_428048]. 
6.7. Tirasemtiv  Accountability  
The patient should be instructed to return all unused tirasemtiv  to the designated clinical site staff 
at each study visit.  Tirasemtiv  accountability is to be conducted by [CONTACT_428049].  The dosing diaries should also be refere nced 
when completing drug accountability. 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 48 7. ADVERSE EVENTS AND S AFETY ASSESSMENTS  
7.1. Definition s  
7.1.1. Adverse Event  
An adverse event ( AE) is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal  product and which does not necessarily have a 
causal relationship with this treatment.   
Consider the following information when determining whether or not to record a clinically 
significant test result, medical condition or other incident on the AE eCRF: 
• From the time of informed consent to first administration of tirasemtiv  record only 
AEs which are related to a study protocol-mandated procedure 
• New symptoms or diagnoses reported/found between the time of signing of informed consent and the first administration of study drug will be recorded as medical history 
on the CY 4033 medical history eCRF  
• Conditions newly detected or diagnosed after the first  administration of tirasemtiv  on 
the CY [ADDRESS_541131] been present but undetected 
prior to the start of the study should be recorded as AEs  
• All AEs (regardless of relationship to study drug) should be recorded from first 
administration of tirasemtiv  through the end of the safety reporting period (see 
Section 7.5, Reporting Period for A dverse Events )    
• An abnormal lab test result should not be recorded as an AE unless it is assessed by [CONTACT_152391] (e.g., associated with clinical signs or 
symptoms, requires intervention, results in a SAE, or results in study termination or interruption/discontinuation of study treatment)   
• Conditions listed on the medical history eCRF known to have been present prior to 
the start of the study that increase in severity or frequency aft er administration of 
study drug should be recorded as AEs  
• Signs, symptoms, or the clinical sequela/sequelae of a suspected drug interaction 
should be recorded as AEs  
• Signs, symptoms, or the clinical sequela/sequelae of a suspected overdose of either 
tirasem tiv or a concurrent medication (overdose per se s hould not be reported as an 
AE) should be recorded as AEs 
• New and/or exacerbated symptoms of ALS (i.e., those not listed on the medical 
history eCRF) should be recorded as AEs  
Issues Not Considered AEs 
• Medical or surgical procedures (e.g., endoscopy, appendectomy); planned prior to the 
patient enrolling into the study  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 49 • Situations where the patient is hospi[INVESTIGATOR_428013] (e.g., social, diagnostic, or convenience admissi ons to a hospi[INVESTIGATOR_307]) 
• Fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not represent a clinically significant change after the first dose of 
study drug 
• Abnormal laboratory or diagnostic test finding s after the first dose of tirasemtiv  that 
are assessed by [CONTACT_428050] 
7.1.2. Serious Adverse Events  
An SAE is any AE that  results in any of the following outcomes: 
Death AE resulted in death  
Life threatenin g The AE placed the patient at immediate risk of death.  It does not refer to an 
event that hypothetically might have caused death if it were more severe, prolonged, or untreated. 
Hospi[INVESTIGATOR_428014].  Hospi[INVESTIGATOR_428015].  Admission to palliative unit or hospi[INVESTIGATOR_428016] a hospi[INVESTIGATOR_059].  When in doubt as to whether 
‘hospi[INVESTIGATOR_059]’ occurred, consult the Sponsor’s Medical Monitor, or 
designee. 
Disability/ 
Incapacity  Resulted in a persistent or significant incapacity or substantial disruption of the patient’s ability to c onduct normal life functions. This definition is not 
intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) that may tempor arily interfere with or 
prevent everyday life functions but do not constitute a substantial or permanent disruption. 
Congenital 
Anomaly/Birth 
Defect An adverse outcome in a child or fetus of a patient exposed to tirasemtiv  
before conception or during pregnancy. 
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541132] required medical or surgical intervention to prevent 
one of the outcomes listed above.  Examples of such events are intensi ve 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059].  The 
development of drug dependency or drug abuse would also be examples of 
important medical events.   If in doubt as to whether or not an event qualifies 
as a “medically significant event”, consult the Sponsor’s Medical Monitor, or 
designee. 
7.2. Adverse Event Severity  
The severity of AEs will be assessed using the National Cancer Institute (NCI) CTCAE, 
version 4.0 as defined  below: 
• Grade 1 (Mild) – Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
• Grade 2 (Moderate) – Moderate; minimal, local or non -invasive intervention 
indicated; limiting age -appropriate activities of daily living 
• Grade 3 (Severe) – Severe or medically significant but not immediately life -
threatening; hospi[INVESTIGATOR_3111]; disabling; limiting self -care activities of daily living   
• Grade 4 ( Life-Threatening) – Life-threatening consequences; urgent intervention 
indicated  
• Grade 5 (Fatal) – Death due to AE  
Notes:  
• AE severity and seriousness are assessed independently.  ‘Severity’ characterizes the 
intensity of an AE.  ‘Serious’ is a regulatory definition and ser ves as a guide to the 
Sponsor for defining regulatory reporting obligations (see definition in Section  7.1.2) 
• Note that “life -threatening” in the criteria for “seriousness” has a more immediate 
definition than the CTCAE definition of “life -threatening”.  Thus, an AE may be 
CTCAE Grade 4 in severity and still not meet the SAE definition of “life -
threatening”.  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 51 7.3. Assessment of Causality to Tirasemtiv  
The relationship of each AE to tirasemtiv  should be evaluated by [CONTACT_366634]:  
Related There is evidence to suggest a causal relationship between the drug and the AE, 
such as an event that is uncommon and known to be strongly associated with drug exposure (e.g. angioedema, hepatic injury, Stevens-Johnson Syndrome) or an 
event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug (e.g. tendon rupture) 
Unrelated  Another cause of the AE is more plausible (e.g., due to underlying dise ase or 
occurs commonly in the study population), or a temporal sequence cannot be established between  the onset of the AE and administration of the study treatment, 
or a causal relationship is considered biologically implausible 
The assessment of causalit y will be based on the information available, and may be changed 
upon receipt of additional information. 
7.4. Procedures for Eliciting and Recording Adverse Events  
Investigator and study site personnel will report all AEs and SAEs whether elicited during patient questioning, discovered during physical examination, laboratory testing and/or other 
methods by [CONTACT_428051]/or SAE Report Form, as appropriate. 
7.4.1. Eliciting A dverse Events  
Use of an open -ended or non-directed method of questioning should be used at each study visit 
to elicit the reporting of AEs.  
7.4.2. Recording of Adverse Events  
When an AE occurs, the Investigator will review all documentation (e.g., hospi[INVESTIGATOR_1088], 
laboratory and diagnostic reports) relevant to the event.   
The following information should be recorded on the AE  eCRF: 
• Description including onset and resolution dates 
• Whether serious ness criteria was met  
• Severity 
• Relationship to tirasemtiv  
• Outcome 
7.4.3. Adverse Event Term  
In general, the use of a unifying diagnosis is preferred to the listing out of  individual 
signs/symptoms.   Groupi[INVESTIGATOR_44971] a diagnosis should only be done if each component 
sign and/or symptom is a medically confirmed component of a diagnosis as evidenced by 
[CONTACT_45033].  If any aspect of the sign or symptom does not fit into a classic 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 52 pattern of the diagnosis, report the individual symptom as a separate AE.  Medical or surgical 
procedures (e.g., endoscopy, appendectomy) should not be reported as an AE term.  The AE term 
should be the me dical condition that led to the procedure (e.g., appendicitis instead of 
appendectomy ). 
7.4.4. Recording Serious Adverse Events  
Record SAE terms on both the AE  eCRF and an SAE Report Form.   The following should be 
considered when recording SAEs: 
• Death is an outco me and should not be used as an SAE term.  The cause of death 
should be the only event that has the outcome of death 
• The surgical or diagnostic procedure should not be recorded as the SAE  term. The 
condition which led to the procedure requiring hospi[INVESTIGATOR_428017].  Capture the procedure in the description of events as part of the action taken in 
response to the illness /condition . 
• The onset date of an SAE is when the AE met any one of the defined serious criteria 
• The resolution date for an SAE with a fatal outcome is the date of death.  
7.4.5. Pregnancy  
Complete a Pregnancy Report Form and fax or email the completed form to the fax number or 
email address on the form within [ADDRESS_541133] is positive, the pregnancy should be immediately reported to the Investigator and 
Sponsor.  Any  female patient who becomes pregnant during the study is not eligible to continue 
in the study and should complete the end of study procedures at that time .   Any male patient 
whose partner becomes pregnant may continue with the study but will prevent further fetal exposure by [CONTACT_2329] a condom during sexual intercourse. 
Complete pregnancy information, including the outcome of the pregnancy, should be collected in 
the source documents on the female patient or partner of a male patient (if the partner is willing).  
In the absence of complications, follow-up after delivery will be no longer than eight  weeks.  
Abortion, whether accidental, therapeutic, or spontaneous, should be reported as an SAE.  Congenital anomalies or birth defects should also be reported as defined by [CONTACT_941] ‘serious’ criterion 
(see definitions Section  7.1.2). 
Any SAE occu rring as a result of a post-study pregnancy and considered reasonably related to 
the tirasemtiv  by [CONTACT_284453]. 
7.5. Reporting Period for Adverse Events  
The safety reporting period for all AEs is from the first administration of tirasemtiv  through 
28 days after the patient’s last dose of tirasemtiv .  However, all AEs associated with a protocol-
mandated procedure are to be collected from the time of informed consent.  All SAEs that occur 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 53 after the safety reporting period and  are considered tirasemtiv -related in the opi[INVESTIGATOR_428018].  
7.5.1. Follow-Up of Adverse Events  
After the initial recording of an AE, the Investigator should proactively follow the patient.  Any 
non-serious AEs th at are still on -going at the end of the study should be reviewed to determine if 
further follow -up is required.  The Investigator will document on the AE  eCRF any/all on -going 
non-serious AEs that will not be followed further (and the rationale ) after the patient exits the 
study.  If in doubt, the Investigator should consult the Sponsor’s Medical Monitor.   
The Sponsor may request that the Investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations to elucidate as fully as possible the nature and/or 
causality of any AE.   
All SAEs should be followed until significant changes return to baseline, the condition stabilizes, 
is no longer considered clinically significant by [CONTACT_737], or the patient dies, withdraws 
consent, or study closure .  All non-serious AEs will be followed through the safety reporting 
period.  Certain non-serious AEs of interest may be followed until resolution, return to baseline, or study closure. 
7.6. Serious Adverse Events  Require Immediate Reporting 
Within 24 hours of the study site’s knowledge of an SAE, Investigators are to report the event to 
the Sponsor, regardless of relationship of the event to tirasemtiv . 
For initial SAE reports, available details of the event are to be recorded on an SAE Repo rt Form.  
At a minimum, the following must be included: 
• Patient number 
• Date of event onset  
• Seriousness criterion or criteria  
• Description of the event 
• Dose of tirasemtiv   
• Causality assessment  
If not all information regarding an SAE is initially available, t he site should not wait to receive 
additional information before reporting the event to the Sponsor within 24 hours.   
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541134] errors, minima, and maxima. For categorical endpoints, frequencies and percentages will be given. For time- to-event endpoints, the number of patients at risk, 
number of events, the median and 95% confidence intervals (CI) of the median, and quartiles will be provided by [CONTACT_5263]-Meier method.  
Assumptions for statistical models will be evaluated. If assumptions are substantially violated, 
alternative analysis methods will be considere d. Missing data will not be imputed unless 
specified.  
Two baseline values  will be used in this study. One is the CY 4033 baseline value which will be 
the assessment at the Follow -Up Visit ( Week 56) in CY [ADDRESS_541135] randomization in CY 4031 (the early -start treatment 
group) and the delayed -start treatment group (patients who previously received placebo at the 
first randomization in CY 4031 and started tirasemtiv  during CY 4033).  Analyses will also be 
conducted to compare the effect of  tirasemtiv  in CY 4031 and CY 4033 within the delayed- start 
treatment group and the early- start treatment group separately.  If data permits, the above 
comparisons will be performed by [CONTACT_428052]. 
8.1.2. Sample Size  
Approximately 350 patients from the sites that participated in  the CY 4031 study are expected to 
be enrolled in the CY 4033 study. All patients will begin dosing with 125  mg of tirasemtiv  twice 
daily for a period of 4 weeks and titrate to the patient’s  tolerable dose level (250 mg, 375 mg or 
500 mg per day). At any point in time, patients who cannot tolerate the current dose level may 
return to their previously tolerated dose level. 
8.2. Analysis Sets 
8.2.1. Safety Analysis Set (S AS) 
The SAS will consist of all patients who are enrolled and receive at least one dose of tirasemtiv  
in the CY 4033 study.  
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 55 8.2.2. Efficacy Analysis Set ( EAS) 
The EAS will consist of all patients who are enrolled in the CY [ADDRESS_541136] one efficacy outcome assessment during the CY 4033 
study. 
8.2.3. Pharmacokinetic Set (PKS)  
The PKS will consist of all patients with at least one evaluable PK concentration, provided they 
have no major protocol violations that could affect the PK of tirasemtiv . 
8.3. Study Endpoints  
8.3.1. Primary Endpoint  
The incidence of adverse events (AEs) in the patient population during the CY 4033 study. 
8.3.2. Secondary Endpoints  
[IP_ADDRESS]. Time-to-Event Endpoints  
There will be two time frames: 1) from the baseline in CY 4031 to the end of the CY 4033 study ; 
2) from the CY [ADDRESS_541137] occurrence of respi[INVESTIGATOR_5448] (defined as tracheostomy or the use of non-invasive ventilation for ≥22 hours per day for ≥10 consecutive days) or death  
3. Time to death  
[IP_ADDRESS]. Change from Baseline Endpoints  
1. Decline in percent predicted SVC from CY 4031 baseline to Week 24 and to Week 48  of 
CY 4033  
2. Decline in percent predicted SVC from CY 4033 baseline to Week 24 and to Week 48 of CY 4033  
3. Decline in ALSFRS -R score from CY 4031 baseline to Week 24 and to Week 48  of 
CY 4033 
4. Decline in ALSFRS -R score from CY 4033 baseline to Week 24 and to Week 48 of 
CY 4033 
[IP_ADDRESS]. Slope Endpoints  
1. Slopes of the changes from baseline in percent predicted SVC and ALSFRS- R score 
during the first [ADDRESS_541138] 48 weeks of either CY 4031 or CY 4033 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 56 8.4. Statistical Analyses  
8.4.1. Patient Disposition  
The total number of patients who will receive tirasemtiv , number of patients who complete and 
discontinue from the study treatment by [INVESTIGATOR_135] 12 weeks interval will be presented overall and by 
[CONTACT_428053]-start and delayed- start treatment group s as well as the maintenance dose level, as 
determined according to the clinical review.  
8.4.2. Demographics and Other Baseline Characteristics  
Patient demographic (i.e., age, gender, race, and ethnicity ) and other baseline characteristics will 
be summarized overall and by [CONTACT_428053]-start and the delayed -start treatment group s, as well as 
the maintenance dose level and overall using descriptive statistics for the SAS and EAS 
separately.  
8.4.3. Efficacy Analyses 
[IP_ADDRESS]. Change from Baseline Endpoints  
Analyses for change from baseline endpoints will be performed with the methods below based 
on the EAS.  
The change from baseline endpoints will be  summarized descriptively by [CONTACT_428053]-start and the 
delayed-start treatment groups , maintenance dose level and overall at each clinical visit in the 
CY [ADDRESS_541139] Model Rep eated Measures (MMRM) model -based method which will include the early -
start and the delayed-start treatment  group, CY 4031 baseline value, visit, riluzole use/non- use as 
well as interaction terms of the early-start and the delayed -start treatment  group-by-baseline, the 
early-start and the delayed-start treatment  group-by-visit with an unstructured covariance matrix. 
The least-squares mean of the difference of the early-start and the delayed-start treatment groups, 
standard error of the difference, and 95 % CI of the difference will be presented .    
Slope endpoints will be analyzed using a mixed model which will include the early -start and the 
delayed-start treatment  group, CY 4031 baseline value, time, riluzole use/non-use as well as 
interaction terms of the early-start and the delayed-start treatment  group-by-baseline, early and 
delayed start  treatment  group-by-time, assuming random slope effect. The estimated slope and 
the slope difference as well as their standard errors will be presented .   
[IP_ADDRESS]. Time-to-Event Endpoints 
Analyses for time-to-event endpoints will be performed with the methods below based on the 
SAS. The patients will be censored to their last contact [CONTACT_428054].  
The multiple time to events will be analyzed using app roaches in (Saville, Herring et al. 2010), 
Wei–Lin–Weissfeld  method (WLW).  
A proportional hazards Cox regression model including treatment group, riluzole use/non-use, 
and SVC percent predicted baseline will be used to estimate the hazards ratio and its 95% CI  
between the early -start treatment group  and the delay- start treatment group with delay -start 
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541140] will be conducted in this study. Comparisons between the delay ed-
start treatment group and the early -start treatment group will be presented using the  nominal p-
values at the two -sided 5% significance level.  
To address multiple comparisons in the study, Hochberg and Holm p-values will be provided for 
the key secondary analyses that will be pre -specified in the statistical analysis plan.  
8.4.5. Sensitivity Analysis 
Sensitivity  analysis will be conducted in this study taking into account the extent of missing data  
as well as censoring algorithm for the time -to-event endpoints. 
8.4.6. Subgroup Efficacy Analyses 
Analyses of the efficacy endpoint s in subgroups may be conducted when data permit. S ubgroups 
based on gender, age group (<65, > 65 years old), geographic region (North America vs. Europe) 
etc. might be considered when data permit.  
8.5. Safety Analysis 
All safety data collected on or after the date that tirasemtiv  was first dispensed in the CY [ADDRESS_541141] dose of tirasemtiv  plus 28 days in the CY 4033 study will be 
summarized overall, by [CONTACT_428053] -start and the delayed-start treatment group s and by 
[CONTACT_428055] (250  mg, 375 mg, and 500 mg) received separately.  
8.5.1. Adverse Events  
A treatment -emergent adverse event ( TEAE) is an AE with an onset after initiation of study drug 
dosing in CY 4033, or an AE present at initiation of study drug dosing that worsens in severity 
after initiation of study dr ug dosing. AE s will be coded using the Medical Dictionary for 
Regulatory Activities (MedDRA) Preferred Terms and grouped by [CONTACT_1196].  The 
version of the MedDRA dictionary will be noted in the report. AEs  will be classified according 
to CTCAE grad e.  
TEAEs will be assigned to the maintenance dose level, or to the total daily dose level 
administered immediately prior to the onset of the TEAE during the CY 4033 treatment.   
If a TEAE continues after a change in total daily dose level without an increa se in intensity, it 
will be assigned only to the total daily dose level at which it initiated.  If a  TEAE continues and 
worsens in intensity after a change in dose level, it will be assigned both to the total daily dose 
level at which it initiated and to the total daily dose level at which it worsened.  If a TE AE 
resolves during continued treatment at the same total daily dose level at which it initiated but 
then recurs following a change in total daily dose level, it will be assigned both to the total dail y 
dose level at which it initiated and resolved and again at the total daily dose level at which it re -
initiated.   
Protocol CY 4033   CONFIDENTIAL  
Version: [ADDRESS_541142] per the early and delayed -start treatment  group 
and preferred term .  The above AE summaries will also be performed by [CONTACT_428056]-
use if appropriate.  The above TEAE summaries will be repeated by [CONTACT_428057] , 
total daily dose level administered immediately prior to the  AE onset and overall separately . 
The prevalence of adverse events will also be summarized by [CONTACT_428053] -start and delayed -start 
treatment groups and maintenance dose level . The treatment associated with an AE in this 
summary will be the total daily dose level the patient was receiving when the AE began as well 
as any total daily dose level the patient received while the AE continued. 
8.5.2. Other Safety Assessments  
The death incidence will be summarized descriptively by [CONTACT_428053] -start and the delayed -start 
treatment  groups, maintenance dose level and overall. Weight change from baseline will be 
analyzed by [CONTACT_428058]. Clinical laboratory data, vital signs, ECGs, neurological 
exams, physical exams, and falls assessments will be descriptively summarized b y the early-start 
and the delayed-start treatment groups, maintenance dose level and overall separately. The death 
incidence density will be provided by [CONTACT_428053] -start and the delayed-start treatment group s, 
adjusting for patients’ actual treatment duration from the open-label lead -in dose of CY 4031to 
the end of the CY 4033 study.  The ratio of death incidence density and 95% CI in the early -start 
treatment group  relative to the delayed -start treatment group  will be calculated using Poisson 
regression.  
8.5.3. Suicidality Assessments  
Suicidality assessment  will be summarized descriptively by [CONTACT_428053]-start and the delayed-start 
treatment  groups and maintenance dose level overall.  
8.6. Study Drug Exposure  
Descriptive statistics will be provided by [CONTACT_428053] -start and the delayed -start treatment group s, 
maintenance dose level of tirasemtiv , the total exposure and the duration of tirasemtiv  treatment . 
8.7. Concomitant Medication  
Concomitant medications taken between the first dose of study drug of CY [ADDRESS_541143] dose of study drug will be summarized and classified by [CONTACT_428059] -start and the delayed -start treatment  groups, maintenance dose level , 
and overall, using the World Health Organization (WHO) Drug dictionary in the most current 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 59 version when the study enrollment starts.  The version of the WHO Drug dictionary will be noted 
in the clinical study . 
8.8. Pharmacokinetic Analysis  
PK analysis will be based on the PKS . Descriptive statistics (arithmetic mean, SD, median, 
minimal, maximum, geometric mean, and coefficient of variation) will be presented for pre -dose 
PK concentration and tirasemtiv  metabolites  overall and  by [CONTACT_428053]-start and the delayed-start 
treatment group s, maintenance dose level  and study visit. The trough concentration will be 
modeled as a function of body weight over time, including covariates that are deemed to be related to the population PK.    
8.9. Pharmacodynamic Analysis  
Pharmacodynamic ( PD) analysis may be performed to graphically explore the relation ship 
between tirasemtiv  concentration and efficacy and safety endpoints.  Additional analysis to 
describe the PK/PD relationship may also be performed, if deemed feasible.  
Statistical analyses will be performed using SAS® version 9. 4 or greater.  
8.10. Change in  Statistical Methods  
All changes in statistical methods that are described in the statistical analysis plan will be 
documented in the clinical study report. 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 60 9. ADMINISTRATIVE ASPECTS 
9.1. Change in Protocol 
There will be no alterations in the protocol without agreement between the Sponsor and the Lead 
Investigator.  
There will be no alterations in the protocol without the express written approval of the Sponsor, 
Investigator, the IRB/ EC/REB, and regulatory authorities, as applicable. 
9.2. Initiation Visit  
Prior to the s tart of the clinical study, the representative(s) of the Sponsor will meet with the 
Investigator(s) and appropriate clinical staff to familiarize the Investigator and clinical staff with the materials necessary for conducting the clinical study.  
9.3. Disclosure  
All information provided regarding the study, as well as all information collected/documented 
during the course of the study, will be regarded as confidential.  The Investigator agrees not to disclose such information in any way without prior written permission from the Sponsor. 
Any publication of the results, either in part or in total (e.g., articles in journals or newspapers, 
oral presentations, abstracts, etc.) by [CONTACT_737](s) or their representative(s), shall require prior notification and review, within a reasonable time frame, by [CONTACT_1034], and cannot be 
made in violation of the Sponsor’s confidentiality restrictions or to the detriment of the 
Sponsor’s intellectual property rights. 
9.4. Monitoring  
The Sponsor will designate site monitors who wil l be responsible for monitoring this clinical 
trial.  The site monitor will monitor the study conduct, proper eCRF and source documentation 
completion and retention, and accurate study drug accountability.  To this end, the monitor will visit the study site at suitable intervals and be in frequent contact [CONTACT_352536].  It is essential that the site monitor have access to all documents (related to the 
study and the individual participants) at any time these are requested.   In turn, the site monitor 
will adhere to all requirements for patient confidentiality as outlined in the ICF.  The Investigator 
and other study personnel will be expected to cooperate with the site monitor, to be available during a portion of the monitoring visit to answer questions, and to provide any missing information. 
9.5. Institutional Review Board / Ethics Committee  / Research Ethics 
Board 
In accordance with the US Code of Federal Regulations, 21 CFR 56, the protocol, advertisement 
(if applicable), and ICF will be submitted to the IRB/ EC/REB for review and subsequent written 
approval by [CONTACT_1201]/ EC/REB must be received before proceeding.  The Sponsor will supply 
relevant material for the Investigator to submit to the IRB/EC/REB  for the protocol’s review and 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 61 approval.  Verification of the IRB/ EC/REB unconditional approval of the protocol and the 
written ICF statement will be transmitted to the Investigator.  
The IRB/EC/REB will be informed by [CONTACT_352537].  Approval for protocol amendments will be transmitted in 
writing to the Investigator.  If requested, the Investigator will permit audits by [CONTACT_1201]/EC/REB  
and regulatory inspections by [CONTACT_20618]/documents. 
The Inves tigator will provide the IRB/EC/REB  with progress reports at appropriate intervals (not 
to exceed one year) and a Study Progress Report following the completion, termination, or 
discontinuation of the Investigator’s participation in the study. 
9.6. Informed Con sent 
Written informed consent for this  study will be obtained from all patients before 
protocol-specific Day 1 procedures are carried out.  If a patient is physically unable to sign 
consent, a Legal Designee of the patient may sign ICF on their behalf if verbal consent is given 
by [CONTACT_102]. The ICF generated by [CONTACT_737] (or designee) will be approved (along with 
the protocol) by [CONTACT_1201]/ EC/REB and will be acceptable to the Sponsor. 
The Investigator (or designee) will explain the nature of the study and the action of the test product.  The patients will be informed that participation is voluntary and that they can withdraw from the study at any time.  In accordance with 21 CFR 50, informed consent shall be 
documented by [CONTACT_2224] a written ICF approved by [CONTACT_1201]/ EC/REB and will be signed by [CONTACT_4677], or their Legal Designee, prior to protocol- specific procedures being performed.   The 
patient will be given a copy of the signed ICF  and the original will be maintained with the 
patient’s records.   A copy of the IRB/ EC/REB-approved site- specific ICF must be sent to the 
Sponsor (or designee).   
9.7. Records 
The results from data collected during the study will be recorded in the patient’s eCRF.  To maintain confidentiality, the patients will be identified only by [CONTACT_15750]. 
The completed eCRFs will be transferred to the Sponsor or designee.  All source documents, records, and reports will be retained by [CONTACT_22298] 21 CFR 312.62(c).  All primary data, or copi[INVESTIGATOR_20583] (e.g., laboratory records, source documents, correspondence, 
photographs, and computer records), which are a result of the original observations and activities 
of the study and are necessary for the reconstruction and evaluation of any study report, will be retained in the study site archives.  
9.8. Reference to Good Clinical Practices (GCP)  
The study procedures outlined in this protocol will be conducted in accordance with the CFR governing Protection of Human Subjects (21 CFR 50), Financial Disclosure by [CONTACT_6230] (21 CFR 54), IRBs (21 CFR 56), Investigational New Drug Application 
(21 CFR 312), and Applications for FDA Approval to Market a New Drug (21 CFR 314), as 
appropriate.  As such, these sections of U.S. Title 21 CFR, along with the applicable ICH 
Guidelines, are commonly known as Good Clinical Practices (GCP). 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 62 10. REFERENCES  
Hwee, D., A. Kennedy, et al. (2014) "Fast Skeletal Muscle Troponin Activator tirasemtiv  
Increases Muscle Function and Performance in the B6SJL -SOD1G93A ALS Mouse 
Model." PLoS One DOI: 10.1371/journal.pone.0096921. 
Kiernan, M., S. Vucic, et al. (2011). "Amyotrophic lateral sclerosis." Lancet 377(9769): 942-
955. 
Lacomblez, L., G. Bensimon, et al. (1996). "Dose-ranging study of riluzole in amyotrophic 
lateral sclerosis." The Lancet  347: 1425-1431. 
Russell, A., J. Hartman, et al. (2012). "Activation of fast skeletal muscle troponin as a potential 
therapeutic approach for treating neuromuscular diseases." Nat Med  18(3): 452-455. 
Saville, B. R., A. H. Herring, et al. (2010). A Robust Method for comparing Two Treatments in a 
Confirmatory Clinical Trial via Multivariate Time -to-event Met hods that jointly 
incorporate information from longitudinal and Time- to-event Data. Stat Med. Author 
Manuscript : 29(21): 75-85. 
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 63 APPENDIX A. SCHEDULE OF EVENTS 
Procedures  Day 1 
Clinic Week 2 
Call Week 4 
Clinic Week 63 
PI/Sub-I 
Call Week 8 
Clinic Week 10 
Call Week 12 
Clinic Week 24 
Clinic  
Week 36 
Clinic Week 48 
Clinic Every 12 
Weeks 
Ongoing 
Clinic Tirasemtiv  
Disc Clinic 
Visit Tirasemtiv  
Disc Phone 
Call 28 Day 
Safety 
Follow-up 
Clinic Visit 28 Day 
Safety 
Follow-up 
Phone Call 
Informed Consent  X               
Inc/Exc C riteria X               
Demographic Data  X               
Physical Examination  X               
Concomitant Meds  X X X X X X X X X X X X X X X 
Vital Signs  X  X  X  X X X X X X  X  
Clinical Safety Labs1 X  X  X  X X X X X X  X  
Serum Pregnancy  Test2 X       X  X  X2    
PK Sample4       X X  X  X  X  
SVC X  X  X  X X X X X X  X  
ALSFRS-R X  X  X  X X X X X X X X X 
Suicidality Assessment  X  X  X  X X X X X X X X X 
AE Assessment  X X X X X X X X X X X X X X X 
Tirasemtiv  Dosing X X X X X X X X X X X     
[ADDRESS_541144] with patient by [CONTACT_976] [INVESTIGATOR_428019] h prescriptive authority in their local jurisdiction   
4 PK Sample to be collected every 24 weeks  after the Week 48 Clinic Visit as well as Tirasemtiv  Discontinuation and 28 Day Safety Follow -Up Visits  
 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 64 APPENDIX B.  SUBSTRATES OF CYP2B6, 2C8 , 2C9, AND 2C19 
2B6 2C8 2C9 2C19 
artemisinin  amodiaquine  NSAIDs:  PPIs: 
bupropi[INVESTIGATOR_428020]  S-naproxen→Nor  Anti-epi[INVESTIGATOR_23698]:  
meperidine   pi[INVESTIGATOR_428021]→Nor  
methadone   suprofen phenytoin(O)  
nevirapi[INVESTIGATOR_428022] 
 S-mephenytoin  
propafol  tolbutamide  phenobarbitone  
selegiline   glipi[INVESTIGATOR_428023]: 
sorafenib  Angiotensin II Blocker s: amitriptyline  
  losartan carisoprodol  
  irbesartan  citalopram  
  Sulfonylureas:  chloramphenicol  
  glyburide  clomipramine  
  glibenclamide  clopi[INVESTIGATOR_428024] N -DeME 
  Other: indomethacin  
  amitriptyline  labetalol 
  celecoxib  R-mephobarbital  
  fluoxetine  moclobemide  
  fluvastatin  nelfinavir  
  glyburide  nilutamide  
  nateglinide  primidone  
  phenytoin -4-OH progesterone  
  rosiglitazone  proguanil  
  tamoxifen  propranolol  
  torsemide  teniposide  
  valproic acid  R-warfarin→[ADDRESS_541145]   
http://medicine.iupui.edu/clinpharm/ddis/main -table/ 
Protocol CY 4033   CONFIDENTIAL  
Version: 13  July 2016 Page 65 APPENDIX C. SUBSTRATES,  INHIBITORS AND INDUCERS OF CYP1A2 
Substrates  Inhibitors  Inducers  
amitriptyline  fluvoxamine* ** broccoli 
caffeine ciprofloxacin***  brussel sprouts  
clomipramine  cimetidine*  carbanazepi[INVESTIGATOR_428025]-grilled meat  
cyclobenzaprine  efavirenz insulin 
duloxetine  fluoroquinolones  methylcholanthrene  
estradiol fluvoxamine  modafinil  
fluvoxamine furafylline  nafcillin 
haloperidol  interferon  beta-naphthoflavone  
imipramine N -DeMe methoxsalen  omeprazole  
mexiletine  mibefradil  rifampin 
nabumetone  ticlopi[INVESTIGATOR_428026]1    
acetaminophen→NAPQI    
propranolol    
riluzole   
ropi[INVESTIGATOR_428027]    
(R)warfarin    
zileuton   
zolmitriptan    
***strong inhibitor, *weak inhibitor  
http://medicine.iupui.edu/clinpharm/ddis/m ain-table/ 